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 Obesity is characterized by chronic oxidative and inflammatory stress, and 
adipose tissue is a significant source of inflammatory cytokines.   Previous studies 
demonstrated that dairy products (rich in calcium and leucine) can alleviate obesity-
associated inflammatory stress through suppression of 1, 25-dihydroxycholecalciferol 
(calcitriol) with calcium and the high leucine content in dairy.  We have also shown 
leucine treatment increases anti-inflammatory adiponectin expression and decreases pro-
inflammatory cytokines TNF- [alpha], MCP-1, and IL-6 expression in adipocytes.  
Therefore, we sought to determine if these alterations in inflammatory cytokine 
production could have a functional effect on the inflammatory process, specifically 
monocyte – endothelial cell adhesion as this is one of the initial events of the 
inflammatory process.  We demonstrate that leucine treatment of adipocytes reduces 
monocyte CD11b expression, endothelial cell ICAM-1 expression and, consequently, 
monocyte – endothelial cell adhesion in vitro while calcitriol exerted the opposite effects.  
Furthermore, plasma samples from obese individuals consuming high dairy diets (> 
[greater than] 3.5 servings/day) over a 12-week period reduced monocyte – endothelial 
cell adhesion, ex vivo.  Recently, adipocyte derived microvesicles (ADMs) have been 
suggested to play a role in communication between adipose tissue and systemic 
circulation, so we sought to determine if adiponectin present on ADMs was responsible 
for the anti-inflammatory effects we have observed when treating adipocytes with 
leucine.  Therefore, after adipocytes were treated for 48 hrs with leucine, the whole 
conditioned media (CM), purified ADMs, and remaining supernatant were applied to 
human peripheral blood to measure monocyte CD11b expression.  Compared to control, 
 v 
leucine CM and the isolated ADMs both reduced monocyte CD11b expression while the 
supernatant fraction did not.  Knocking down adiponectin with siRNA attenuated these 
effects, suggesting adiponectin associated with ADMs plays a role in mediating the anti-
inflammatory effects we have observed.  Collectively, these data suggest that dairy 
products can provide beneficial effects at reducing obesity-associated inflammation, and 
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 Overweight and obesity, defined as having a body mass index >25 kg/m
2
 and >30 
kg/m
2
, respectively, is a growing problem in both the United States and worldwide.  
According to the World Health Organization in 2008, 1.4 billion or 35% of the world’s 
population age 20 and older were overweight (1).  Approximately 500 million or 11% of 
the world’s population are obese, and in the United States in 2012, nearly 35% of adults 
age 20 and older are obese (1, 2).  Obesity is associated with increased risk factors for 
multiple chronic diseases including cardiovascular disease, cancer, and type 2 diabetes 
(3), and the cost to treat obesity related diseases was estimated to be $147 billion in the 
United States in 2008 (4). 
 Adipose tissue is a significant source of both reactive oxygen species (ROS) and 
inflammatory cytokines (5, 6). In obesity, enlarged adipocytes produce more pro-
inflammatory cytokines such as tumor necrosis factor alpha (TNF α) and interleukin 6 
(IL-6), and less anti-inflammatory factors such as adiponectin (7, 8). The regulation of 
ROS production and interactions among ROS, cytosolic Ca
2+
 signaling and mitochondrial 
uncoupling have been intensively investigated, and we have shown that calcitriol (1,25-
Dihydroxycholecalciferol) increases ROS production in both murine and human 
adipocytes by inhibiting adipocyte UCP2 expression, thereby increasing mitochondrial 
potential, and increasing cytosolic Ca
2+
 signaling (9).  Accordingly, since dietary calcium 
suppresses calcitriol, high calcium diets may correspondingly decrease adipose tissue 
ROS production and systemic oxidative stress.  Consistent with this concept, increasing 
dietary calcium decreases pro-inflammatory cytokine production and increases 
adiponectin production in mice (10, 11). 
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These data provide a framework to explain a protective effect of dietary calcium 
against oxidative and inflammatory stress.  However, milk also contains high 
concentrations of leucine and bioactive peptides that may further protect against 
oxidative and inflammatory stress.  Leucine has been shown to increase mitochondrial 
UCP2 expression and adiponectin production in differentiated 3T3-L1 adipocytes, and 
promote fatty acid oxidation in C2C12 muscle cells, while calcitriol exerted the opposite 
effects (12).  Furthermore, we have recently confirmed that dairy exerts a significantly 
greater effect on suppressing both local adipose tissue and systemic oxidative and 
inflammatory stress compared to supplemental calcium in mice (11).  Additionally, our 
human data demonstrate that dairy-rich diets result in suppression of oxidative and 
inflammatory biomarkers (11).  In a recent follow-up randomized crossover study in 
overweight and obese subjects, we found that dairy supplementation suppressed both 
oxidative and inflammatory stress within seven days of initiation of supplementation, and 
that these effects increased in magnitude with increased duration of supplementation (13).  
Similar results were found in a 12-week study of metabolic syndrome patients (14). 
The adipose tissue cytokines we have demonstrated to be regulated by calcitriol 
and dairy components include several which affect vascular endothelial and smooth 
muscle cells (e.g. MCP-1, MIF, CD14, TNF-α, IL-6, IL-8, VEGF) and vascular 
infiltration by monocytes (15).  Accordingly, the purpose of this work was to: a) 
determine if the modulation of adipocyte cytokine production observed with leucine and 
dairy treatment has a functional effect on the inflammatory process, b) determine which 
cytokine plays the most prominent role in this process, and c) determine if adipocyte 
derived microparticles can play a role in this process. 
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2.1.0  Adipose Tissue Overview: 
 
The term adipose tissue (AT) refers to loose connective tissue in the body where 
fat is stored (1).  AT is interspersed throughout the body where it can serve a variety of 
functions and play multiple roles.  Various forms of AT are present throughout the body.  
These forms include white adipose tissue (WAT), brown adipose tissue (BAT), and 
beige/brite adipose tissue (1).  Each of these forms are critically important for energy 
metabolism and their functions are tightly regulated (1).  The sections below will discuss 
the various aspects of adipose tissue including the specific cellular components and the 
role those components play in regulating energy metabolism. 
 
2.1.1  Adipocytes: 
The two primary forms of adipose tissue are white adipose tissue (WAT) and 
brown adipose tissue (BAT), whose primary functions are energy storage and 
thermogenesis, respectively (2).  These two distinct forms of AT are comprised of 
different cell types that serve specific roles in each of their respective tissues.  In humans, 
WAT can typically make up 15-20% of the total body mass of a healthy, young adult (1).  
WAT can be found dispersed throughout the body including under the skin 
(subcutaneous), in the abdominal cavity, and around bodily organs (visceral) (1).  The 
most abundant cell type present in WAT is the white adipocyte, or more commonly 
known as the fat cell.  White adipocytes are large (typically 30-70 m in diameter), 
spherical cells filled with a single, large lipid droplet that constitutes ~65% of the cell 
mass (3).  The lipid droplet, due to its size, causes the mitochondria and nucleus to be 
forced up against the cell wall of the plasma membrane (3).   
 7 
The primary function of the white adipocyte is to store energy in the body as fat 
until a demand for energy increases, where the stored fat is mobilized and used 
throughout the body as a source of fuel (1, 3).  Like many other cell types, adipocytes 
have an active glycolytic metabolism, are capable of oxidizing pyruvate and fatty acids 
via the citric acid cycle, and also carry out oxidative phosphorylation (3).  During periods 
of high carbohydrate intake, white adipocytes can convert glucose to fatty acids, which 
are stored in the adipocyte’s lipid droplet as triacylglycerol (TAG) (3).  White adipocytes 
can also store lipid exported from the liver (1, 3).  When fuel sources become scarce, 
lipase enzymes in the adipocyte hydrolyze the stored TAGs and release them as free fatty 
acids into the blood stream to be used as fuel (1, 3).  
BAT is less abundant in adults and more abundant in newborn infants, where it is 
involved in thermogenesis (4).  In adult humans, BAT can be found deep in the neck and 
close to muscle tissues (5, 6).  The predominant cell type present in BAT is the brown 
adipocyte, which is structurally and functionally distinct from white adipocytes (3).  
Compared to white adipocytes, brown adipocytes are typically smaller (20-40 m in 
diameter), polygonal shaped cells that store triglycerides (TAGs) in several, smaller lipid 
droplets per cell (3).  Furthermore, brown adipocytes have more mitochondria and the 
surrounding tissue has a richer supply of capillaries, thus causing the cells to appear 
brown in color (3).  One key genetic difference between white and brown adipocytes is 
the expression of mitochondrial uncoupling protein 1 (UCP1) by brown adipocytes (7).  
UCP1 is a 32 kDa transmembrane protein located on the inner mitochondrial membrane 
that promotes the uncoupling of the mitochondrial electron transport chain from ATP 
synthesis during oxidative phosphorylation and -oxidation of fatty acids, resulting in the 
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dissipation of the mitochondrial membrane potential and allowing the energy to be 
dissipated as heat (4).  This controlled exothermic release of stored energy occurs during 
periods of cold exposure in order to increase the core body temperature, a process known 
as non-shivering thermogenesis (3).  Upon exposure to a cold environment, the 
sympathetic nervous system activates 3-adrenergic receptors in brown adipose tissue to 
initiate lipolysis and activation of UCP1, which will use the mitochondrial membrane 
potential generated during electron transport from lipolysis to bypass ATP synthase, thus 
allowing the stored energy to be dissipated as heat to warm the body (8).  Consequently, 
BAT is highly metabolically active and can be detected as hot spots of radiolabeled 
glucose uptake by positron emission tomography – computed tomography (PET-CT) (2).   
Both white and brown adipocytes are believed to be from a mesodermal origin, 
but different mesenchymal stem cell (MSC) lineages (2).  Although the number of steps 
and cell types remain unclear, it is believed that MSCs give rise to a common early 
precursor, known as the adipoblast, which in turn develops into the committed white and 
brown pre-adipocyte and under specific stimulatory conditions will differentiate into 
mature white and brown adipocytes (2, 9).  The process of pre-adipocytes differentiating 
into mature adipocytes is collectively known as adipogenesis (9).  The transition from 
pre-adipocyte to mature adipocyte is thought to occur in four stages:  growth arrest, 
clonal expansion, early differentiation, and terminal differentiation (9).  These stages are 
organized by a cascade of transcriptional regulators involving the nuclear receptor 
peroxisome proliferator-activated receptor gamma (PPAR) and members of the 
CCAAT-enhancer-binding-protein (C/EBP) family (9).  PPAR activates a variety of 
genes that regulate fatty acid storage and glucose metabolism, and thus is required for 
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adipogenesis, as PPAR knockout mice fail to generate adipose tissue when fed a high fat 
diet (10, 11).  PPAR has two isoforms, namely PPAR1 and PPAR2, in which PPAR2 
seems to be more dominant for adipocyte differentiation (8, 9). The C/EBP family 
consists of five different members:  C/EBP, C/EBP, C/EBP, C/EBP, and CHOP (2).  
During differentiation, these various members are sequentially expressed and help drive 
the differentiation process.  For example, early expression of C/EBP and C/EBP 
promote the expression of C/EBP and PPAR2 later on during the adipogenic program 
(12).  Although both white and brown adipocytes appear to be of a common lineage, 
studies have shown that traditional brown adipocytes are derived from myoblasts and are 
positive for the Myf5 protein while white pre-adipocytes do not express this protein (13).  
Furthermore, two key transcriptional regulatory factors involved in the brown adipogenic 
program are C/EBP and the PR domain-containing protein-16 (PRDM16) (5, 8, 13).  
PRDM16 binds and co-regulates C/EBP, PPAR, PPAR, and PGC-1 to promote 
brown fat-specific gene induction (5, 13).  PGC-1, or peroxisome proliferator-activated 
receptor gamma coactivator 1-, is involved in regulating mitochondrial biogenesis, 
oxidative metabolism, and thermogenesis (14, 15).  The primary physical characteristic of 
adipocyte differentiation is lipid droplet accumulation.  Although many cell types can 
accumulate lipids, adipocytes collect the lipids into either a unilocular lipid droplet 
(WAT) or in smaller multilocular droplets (BAT) surrounded by the protein, perilipin 
(16).   
Although white and brown adipocytes have distinct structural features, 
characteristics and functions, recent evidence suggests a third type of adipocyte known as 
the beige adipocyte (also called inducible brown, brown-in-white, or brite) (17, 18).  The 
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accumulation of beige adipocytes in WAT is often referred to as “browning” of WAT, 
and occurs after extended cold exposure, from 3-adranergic receptor agonists, or from 
exercise-induced myokines, including irisin and meteorin-like. (7, 19).  Recent evidence 
has shown that these beige adipocytes that arise in WAT are not of the traditional Myf5 
positive precursor lineage that give rise to traditional brown adipocytes present in BAT 
depots (20, 21).  Although the exact mechanism of “browning” of white adipose tissue 
remains unclear, some groups claim that the “browning” process arises via the 
transdifferentiation of white adipocytes into beige/brite adipocytes (20, 21).  
Interestingly, “paucilocular” adipocytes (UCP1-positive cells containing lipid droplet 
distribution that is intermediate between brown and white adipocytes) have been reported 
and further suggest an intermediate form of adipocyte that is transitioning from white to 
beige/brite adipocytes (22, 23).  Furthermore, recent data based on genetic labeling of 
adipose cells support the existence of bidirectional interconversion between beige/brite 
and white adipocytes (24).  The “browning” process has become a popular area of 
research due to its therapeutic potential of expending energy without the production of 
ATP and warrants further investigation (7). 
 
2.1.2  Stromal/Vascular Fraction of Adipose Tissue: 
 In addition to adipocytes, adipose tissue is comprised of other cell types 
commonly referred to as the stromal/vascular fraction, which consists of blood vessels 
containing endothelial cells, leukocytes such as monocytes/macrophages, and cells that 
exhibit characteristics of progenitor cells (25).  The stromal/vascular fraction supplies the 
tissue with blood, nutrients and energy to support growth and for energy storage (25).  
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Endothelial cells line the blood vessels wall and play a role in the extravasation of 
leukocytes from blood circulation into the adipose tissue (25).  Specifically, monocytes 
and macrophages are the most prominent leukocyte present in adipose tissue, and can 
secrete a variety of cytokines and chemokines that generate cross-talk between 
adipocytes and the stromal/vascular fraction (26).   
 
2.1.3  Endocrine Function of Adipose Tissue: 
In addition to its role in energy storage, adipose tissue is an active endocrine 
organ that expresses and secretes a variety of peptides and hormones into circulation (27, 
28).  The peptides and hormones produced in adipose tissue are collectively referred to as 
adipokines (29).  Adipokines can act locally, via an autocrine or paracrine action, or 
systemically, via an endocrine action to carry information about the adequacy of the 
energy reserves (TAGs) stored in adipose tissue to other tissues and to the brain (3).  
Under normal conditions, adipokines cause changes in fuel metabolism and feeding 
behavior that will reestablish adequate fuel reserves and, thus, maintain body mass (3).  If 
adipokines are over or under produced, it can result in life-threatening altercations that 
increase the risk for a variety of diseases (3).  The three classic adipose tissue derived 
hormones are leptin, resistin and adiponectin (3). 
The first adipokine, discovered in 1994 by Zhang et al., was the peptide hormone 
leptin, which is a 167 amino acid peptide that, upon reaching the brain, acts on receptors 
in the hypothalamus to change appetite (30).  Leptin essentially messages to the body that 
fat reserves are sufficient, and it promotes a reduction in food intake and increases energy 
expenditure (31).  The leptin receptor is expressed in regions of the brain that are known 
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to regulate feeding behavior called the arcuate nucleus of the hypothalamus (3).  The two 
types of neurons in the arcuate nucleus control fuel intake and metabolism (3).  The first 
type known as orexigenic neurons, stimulate eating by producing and releasing 
neuropeptide Y, which is suppressed by leptin (3).  Furthermore, leptin stimulates the 
second type of neuron called anorexigenic neurons to produce -melanocyte-stimulating 
hormone (-MSH; also called melanocortin), which suppresses appetite (3).  Therefore, 
as adipose tissue mass decreases, leptin levels also decrease (3). 
A second adipose tissue specific adipokine is resistin, which plays a role in 
obesity related insulin resistance, as depletion of circulating resistin by neutralizing 
antibodies in obese mice resulted in improved insulin action (32) and resistin knockout 
mice fed a high fat diet show signs of improved glucose metabolism (33).  The third 
classic adipokine is adiponectin, and will be discussed in detail in subsequent sections. 
 
2.1.4  Adipose Tissue and Inflammation: 
 Adipose tissue can produce multiple factors that can directly interact with the 
immune system, both locally and systemically, to alter the inflammatory response (27).  
Inflammation is a complex biological process by which an organism’s immune system 
responds to an infectious stimuli, pathogen or tissue damage through the recruitment of 
activated immune cells to repair or heal the tissue (34).  Inflammation can be classified as 
either acute or chronic inflammation, where acute inflammation typically refers to an 
initial immune response to a site of infection or damage while chronic inflammation is a 
prolonged version and typically occurs systemically in the organism (1, 3).  Classic signs 
of inflammation are pain, redness, swelling and heat and are typically present at a 
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localized site of tissue damage or infection (35).  Upon stimulation, resident immune 
cells in the tissue will recognize pathogens or tissue damage through expression of 
pattern recognition receptors (PRRs) that recognize molecular patterns of invading 
pathogens or tissue damage (35).  These patterns are distinguishable from host patterns 
and are collectively referred to as pathogen-associated recognition patterns (PAMPs) 
(35).  The activation of these receptors initiates the release of inflammatory mediators by 
the immune cells, which result in vasodilation and subsequent increased blood flow to the 
sites of inflammation (35).  The inflammatory mediators also cause increased adhesion 
molecule expression on the surface of endothelial cells lining the blood vessel to recruit 
additional immune cells to the site, resulting in migration of immune cells through the 
endothelial layer into the tissue to begin repairing the damaged tissue or eliminating the 
pathogen (35).  The following sections will describe the role of the various adipose tissue 
inflammatory mediators, how they are involved in altering the inflammatory response, 
and how obesity alters this process. 
 Obesity is a condition characterized by an excess of adipose tissue that results in 
adverse effects on health by increasing risk for a type 2 diabetes mellitus, cardiovascular 
disease, cancer, sleep apnea, and many others (36).  Obesity, defined as a body mass 
index greater than or equal to 30 kg/m
2
, is caused primarily by excess energy intake, lack 
of physical activity, and genetic susceptibility, which ultimately leads to an alteration of 
energy balance resulting in excessive weight gain (36).  
 Adipose tissue can produce multiple components, such as inflammatory 
cytokines, that can alter inflammation (27), and enlarged or obese adipocytes produce 
more pro-inflammatory cytokines and less anti-inflammatory cytokines compared to non-
 14 
obese adipocytes (27, 36).  This excess production of pro-inflammatory cytokines can 
result in a feed forward cycle that ultimately leads to chronic, systemic inflammation, 
which contributea to obesity related diseases (27, 36).  Furthermore, the transition from 
normal to obese adipose tissue is accompanied by an increase in macrophage infiltration 
in response to the increased production of pro-inflammatory cytokines (37).  
Additionally, obesity also causes a shift in polarization of adipose tissue macrophages 
from an anti-inflammatory state (M2) to a pro-inflammatory state (M1) (38, 39).  It is 
believed that the link between obesity, inflammation, and metabolic complications is 
directly related to the failure of adipose tissue to expand and meet storage demands, 
causing lipid spilling from adipocytes (40, 41).  The free lipids are taken up by resident 
macrophages leading to formation of foam cells, which are then inhibited from 
scavenging the apoptotic adipocytes and can further increase insulin resistance (40, 41). 
 The first inflammatory cytokine demonstrated to be released by adipose tissue is 
tumor necrosis factor alpha (TNF-) (42).  TNF- is a potent pro-inflammatory cytokine 
that is primarily produced by macrophages present in adipose tissue (42).  TNF- is 
involved in recruitment of additional immune cells through activation of various cell 
signaling pathways, such as NF-B and MAPK, that lead to transcriptional activation of 
various proteins and cytokines involved in inflammation (29). TNF- interferes with 
insulin signaling, leading to obesity-induced insulin resistance (43).  This is believed to 
occur through activation of JNK1, which phosphorylates and inactivates insulin receptor 
substrate-1 (IRS1) and, thus, blocks the signal from the insulin receptor to the 
intracellular signaling pathway PI3K/Akt (43).  Conversely, mice lacking TNF- or its 
receptors are protected from obesity-induced insulin resistance and hyperglycemia (43).  
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Free fatty acids can promote TNF- production in macrophages, which can in turn 
promote lipolysis to increase free fatty acid release from adipocytes, causing a feed-
forward cycle of further insulin resistance (44).   
 Additionally, adipose tissue secretes monocyte chemotactic protein 1 (MCP-1), a 
pro-inflammatory chemokine involved in the recruitment of monocytes, memory T cells, 
and dendritic cells to the site of inflammation (45).  MCP-1 production and secretion by 
adipose tissue resident macrophages and adipocytes is positively correlated with the 
expansion of adipose tissue, and increased MCP-1 expression in adipose tissue results in 
increased macrophage infiltration, insulin resistance, and hepatic steatosis associated with 
obesity in mice (45).   
 Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by multiple cell 
types including immune cells, fibroblasts, endothelial cells, skeletal muscle, and adipose 
tissue, and it is positively associated with obesity and insulin resistance (46).  IL-6 is 
primarily involved in fever production and the acute phase response, thus leading to 
production of acute phase proteins, such as C-reactive protein, that is considered a 
clinical marker of systemic inflammation(47).  Although IL-6 seems to be involved with 
glucose metabolism and insulin resistance, the exact mechanism of its actions is currently 
unknown (47).   
 The interleukin 1 (IL-1) family of inflammatory cytokines include 11 different 
members that play a role in the immune and inflammatory response (29).  IL-1 cytokines 
are produced primarily by monocytes, macrophages, fibroblasts, and dendritic cells, and 
they are involved in increasing adhesion molecule expression on the surface of 
endothelial cells to promote immune cell migration from blood to the inflamed tissue 
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(29).  Like most other pro-inflammatory cytokines, IL-1 in adipose tissue is positively 
correlated with the development of obesity.   
 Macrophage inflammatory protein 1  and  (MIF-1 and -1), also known as 
CCL3 and 4, respectively, are pro-inflammatory chemokines produced by macrophages 
to initiate the immune response by activating neutrophils to fight infection or 
inflammation (29).  As with most other pro-inflammatory factors, MIF is also positively 
correlated with the development of obesity.  One of the only anti-inflammatory cytokines 
produced by adipose tissue is adiponectin and will be discussed in detail in the next 
section. 
 
2.2.0  Adiponectin: 
 Adiponectin is one of the most abundant adipokines secreted by adipocytes, with 
circulating plasma levels ranging from 2-20 g/mL in humans with a half-life of 2.5-6 
hours (48).  The gene encoding the adiponectin protein is located on chromosome 3q27, 
which is a locus associated with susceptibility to diabetes and cardiovascular disease 
(49).  Adiponectin is a 247 amino acid protein with an NH2-terminal hyper-variable 
region, a conserved collagen-like domain comprising 22 Gly-X-Y repeats and a COOH-
terminal C1q-like globular domain (50).  Adiponectin is secreted from adipocytes as 
three different oligomeric complexes, which include a trimer, hexamer, and a high 
molecular weight (HMW) multimer consisting of at least 18 monomers (Figure 2-1) (51).  
The trimeric form of adiponectin is assembled through hydrophobic interactions within 
the globular head domain and is stabilized by the non-covalent interactions of the 
collagen-like domains in the triple-helix stalk (52).  The subsequent assembly of the 
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higher ordered structure requires the formation of an intermolecular disulfide bond 
between highly conserved cysteine residues within the hyper-variable region (53).  The 
cysteine residue is located at amino acid 22 (numbering starting after the signal sequence 
domain) and site directed mutagenesis to an alanine residue (C22A) prevents formation 
of the higher ordered oligomeric structures (53). 
 The three forms of adiponectin have been shown to possess different biological 
activities, and the HMW form is considered the major active form in circulation, 
providing the insulin-sensitizing and cardiovascular protective effects observed with 
adiponectin (55, 56).  The synthesis and secretion of adiponectin oligomers in adipocytes 
are tightly regulated by multiple molecular chaperones in the endoplasmic reticulum (ER) 
(52), which include ER protein of 44 kDa (ERp44) (57), ER oxidoreductase 1-L (Ero1-
L) (58), and disulfide-bond A oxidoreductase-like protein (DsbA-L) (59).  ERp44 will 
inhibit the secretion of adiponectin oligomers through a thiol-mediated retention (57).  
Conversely, Ero1-L releases HMW adiponectin that becomes trapped by ERp44 (58), 
while DsbA-L promotes the intracellular assembly and secretion of HMW adiponectin 
(59). 
 Adiponectin exerts its signaling actions through two receptors, adiponectin 
receptor 1 and 2 (AdipoR1 and AdipoR2) (60).  AdipoR1 and AdipoR2 are both seven-
transmembrane receptors that share a 67% homology with one another but differ 
significantly at the amino terminus (52, 61).  Compared to other traditional 7 
transmembrane receptors, the adiponectin receptors have the opposite orientation with the 
carboxyl terminus residing outside the cell and the amino terminus located in the 
cytoplasm (61).  AdipoR1 is ubiquitously throughout the body with the highest 
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expression levels in skeletal muscle, while AdipoR2 is predominantly expressed in the 
liver (60, 61).  Activation of the adiponectin receptors leads to intracellular 
communication through activation of serine/threonine kinases such as AMPK and Akt2, 
increased phospholipase C activity, and small G-proteins such as Rab5, ultimately 
leading to increased magnitude of insulin signaling on target cells to facilitate glucose 
uptake and energy homeostasis (62).   
 
2.2.1  Adiponectin and AMPK Signaling: 
 One way adiponectin sensitizes target tissue to insulin actions is through 
increasing 5’-adenosine monophosphate kinase (AMPK) activity, which stimulates fatty-
acid oxidation, increases PPAR expression, and increases glucose uptake while 
simultaneously inhibiting glycolysis, lipogensis and gluconeogenesis (62).  AMPK is 
activated by factors that signal the need to shift metabolism away from biosynthesis and 
towards energy generation through the increased production of AMP, and is therefore 
considered a key nutrient sensor in the cell (1, 3).  Activation of AMPK occurs during 
periods of nutrient deprivation and exercise, causing the upregulation of ATP-producing 
processes such as fatty acid oxidation (1, 3).  Furthermore, AMPK can directly increase 
insulin sensitivity through phosphorylation of peroxisome proliferator-activated receptor 
 co-activator 1 alpha (PGC-1), a transcription co-activator that plays a critical role in 
mediating mitochondrial biogenesis and oxidative phosphorylation (63).  AMPK is a 
heterotrimeric protein composed of ,  and  subunits that stabilize and activate the 
protein kinase upon interaction of AMP to Bateman repeats of the  subunit (64).  AMPK 
can be phosphorylated on threonine-172 by upstream targets liver kinase B1 (LKB1) and 
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Calcium/calmodulin kinase kinase  (CaMKK) through action of an adaptor protein 
APPL1, which binds to the N-terminus of AdipoR1 (52, 63, 65).  APPL1 also binds to the 
protein kinase Akt2 and the catalytic subunit of phosphoinositide-3-kinase (PI3K) leading 
to increased translocation of GLUT4 to the plasma membrane to transport glucose inside 
the cell for utilization (65).   
 Adiponectin can also exert anti-atherosclerotic effects through modulation of 
multiple points of the inflammatory process (66).  For example, adiponectin prevented 
atherosclerosis by increasing cholesterol efflux from macrophages (67).  Furthermore, in 
human monocyte-derived macrophages, which express the adiponectin receptor, 
adiponectin induced upregulation of IL-10 (68, 69).  Adiponectin also increased 
expression of CD36, acetyl CoA oxidase, and uncoupling protein 2 in skeletal muscle, 
while causing a decrease in CD36 in the liver (70).  In the endothelial cell, adiponectin 
was shown to inhibit the production of inflammatory cytokines and adhesion molecules 
such as intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 
(VCAM) and E-selectin (71).  Furthermore, adiponectin has been shown to increase 
endothelial nitric oxide synthase (eNOS) production leading to the production of nitric 
oxide (NO) in the vasculture to stimulate vasodialation (72).  Additionally, adiponectin 
inhibited TNF- induced activation of NF-B (73).  These results suggest that 





2.3.0  Modulation of Adipose Tissue Function and Energy Balance with 
Dairy Products: 
 Fat mass expansion and accumulation occur through adipocyte hypertrophy, or 
the increase in size of the adipocyte, and adipocyte hyperplasia, or the increase in 
adipocyte number (74).  Typically, adipocyte hyperplasia occurs by proliferation and 
subsequent differentiation of pre-adipocytes, while adipocyte hypertrophy results from 
excessive lipid storage within adipocytes.  Adipocyte hypertrophy is frequently seen in 
obese adipose tissue and is often associated with the remodeling of adipose tissue, 
inflammatory and oxidative stress, all of which contribute to metabolic abnormalities at 
both the local and systemic levels (75).  The sections below will discuss how dairy 
products and specific dairy bioactive components are involved in altering obesity with 
regards to weight management, oxidative stress, and inflammation.  
 
2.3.1  Dairy Overview: 
 The term, dairy products, refers to food products that are produced from the milk 
of mammals.  According to the current MyPlate guidelines, it is recommended that 
children between ages 2-3 years old consume 2 cups of dairy daily, children between 4 
and 8 should consume 2.5 cups per day, while all individuals above the age of 9 should 
consume 3 cups per day (choosemyplate.gov).  All fluid milk products and many foods 
made from milk are considered to be apart of this group, and it is recommended that food 
choices be made from the low-fat or fat free dairy category.   
 Many studies have shown that consumption of dairy products can provide 
multiple health benefits, specifically related to bone health (76).  Dairy products are rich 
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in minerals such as calcium, potassium and vitamin D that are vital to overall health, as 
well as being rich in protein (76).  Calcium is beneficial for building and maintaining 
bone mass and teeth; potassium is beneficial for maintaining a healthy blood pressure; 
vitamin D helps maintain circulating levels of calcium and phosphorous, thereby helping 
maintain healthy bone mass (76).   
 
2.3.2  Dairy and Weight Loss: 
 Although multiple studies have been performed to investigate the relationship 
between dairy consumption and weight loss, the findings from these studies are 
somewhat conflicting.  According to the most recent meta-analysis of randomized 
controlled trials by Chen et al., which focused on the effects of dairy intake on body 
weight and fat in 29 randomized control trials which included 2,441 participants, there is 
not a beneficial effect of increasing dairy consumption on body weight and fat loss in 
long-term studies or studies without energy restriction (77).  However, the meta-analysis 
did find that dairy products may have a modest effect in facilitating weight loss in short-
term or in energy-restricted randomized controlled trials (77).  Specifically, the clinical 
trials discussed in this meta-analysis concluded that increasing dairy intake (1.8-3.3 
servings per day versus 1-2.7 servings of dairy per day for the control group) without 
energy restriction does not significantly affect weight, body fat mass, lean mass, and 
waist circumference (77).  However, the majority of clinical studies with an energy-
restriction diet indicated that dairy-rich diets augment weight loss, fat loss, and reduce 
adiposity.  Specifically, the meta-analysis showed that increased consumption of dairy 
with an energy-restriction diet (500 kcal less than maintenance) led to 1.29 kg greater 
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weight loss, 1.11 kg greater reduction in body fat mass, 0.72 kg gain in body lean mass 
and 2.43 cm additional reduction in waist circumference compared with control groups.  
Wennersberg et al. reported no change in body weight or body fat during 6 months of 3-5 
portions/day of dairy products consumption (78).  However, they did observe positive 
effects on waist circumference in subjects with a low baseline calcium intake (78).  This 
demonstrates the possibility of a threshold in relation to effects on body composition.  
Overall, these studies suggest that the inclusion of 3-5 portions/day of dairy products may 
have modest benefits in facilitating weight loss in energy-restricted diets (76, 77). 
 
2.3.3  Dairy and Oxidative/Inflammatory Stress: 
 Low-grade systemic inflammation is considered as a key etiologic factor in the 
development and progression of cardiovascular disease, type 2 diabetes mellitus, and 
metabolic syndrome (79).  A cross-sectional study suggests that consumption of dairy 
products is inversely associated with low-grade systemic inflammation (80).  It is well 
known that elevated plasma concentrations of C-reactive protein (CRP) and pro-
inflammatory cytokines such as TNF- and IL-6 are associated with an increased risk of 
cardiovascular disease (81).  Additionally, monocyte chemoattractant protein-1 (MCP-1) 
is involved in recruitment of monocytes to sites of vascular inflammation, thereby 
promoting atherosclerosis, and MCP-1 expression is increased in obese individuals (76).  
Furthermore, oxidative stress is a common mediator in the pathogenicity of 
cardiovascular risk factors (76).  Multiple studies have proposed that dairy components 
may play a role in down-regulating genes that encode pro-inflammatory cytokines while 
up-regulating those genes that regulate antioxidant enzymes (76). 
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 Stancliffe et al. demonstrated reduced markers of oxidative stress in overweight 
and obese subjects consuming dairy foods (82).  Specifically, adequate dairy 
consumption (3.5 servings/day) decreased malondialdehyde and oxidized LDL levels 
after 1 week of intervention, with further decreases after the 12 week study (82).  
Similarly, the adequate dairy group exhibited reduced inflammatory markers, including 
TNF-, IL-6 and MCP-1 (82).  Additional studies have shown consumption of dairy 
products rich in cis-9, trans-11 conjugated linoleic acid for 10 weeks showed a reduction 
in the inflammatory markers IL-6, IL-8 and TNF- in 10 healthy subjects (83). Other 
clinical trials have also demonstrated that diets supplemented with dairy resulted in 
suppression of oxidative stress markers (plasma malondialdehyde and F2-isoprostane) 
and lower inflammatory markers (TNF-, IL-6, and MCP-1) in overweight and obese 
subjects (84, 85).  Conversely, Nestel et al. did not observe differences in the oxidative 
stress marker F2-isoprostane in 12 overweight and obese subjects consuming a low-fat 
dairy diet and two high-fat dairy diets (86).  Other clinical studies also found no changes 
in inflammatory markers, oxidative stress markers or cytokine gene expression (78, 87-
89).  However, some of these studies have been performed in subjects that already 
consumed an adequate dairy diet, leaving little room for a slightly higher dairy diet to 
exert its effects.  Other studies have included a 3 week “run-in” period before the trial 
begins.  It is possible that these run-in periods in otherwise inactive individuals allows for 
reductions in baseline levels of oxidative and inflammatory stress markers, leaving little 
room for improvement from the clinical intervention.  Further clinical trials are warranted 
and require carefully design parameters. 
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2.3.4  Calcium Homeostasis: 
Plasma calcium levels are typically maintained at ~2.5 mM (9-10 mg/dL), and 
this level is maintained via endocrine systems that respond to increases or decreases in 




-sensing receptors in the parathyroid (as well as clear 
cells in the thyroid) detects a drop in circulating Ca
2+
.  This initiates the release of 
parathyroid hormone (PTH) from the parathyroid gland, and facilitates the conversion of 
25-hydroxy-Vitamin D (primary form in circulation) to the active form, 1alpha-25 
dihydroxycholecalciferol, also called calcitriol.  This process occurs in the renal proximal 
tubule of the kidneys and is mediatd by 1-alpha hydroxylase activity, which is increased 
in response to the increase in PTH.  Once calcitriol is produced, it acts at multiple sites, 
including the intestine to increase calcium absorption, the kidneys to increase calcium 
reabsorption, and on the bones to mobilize calcium stores.  These actions release calcium 
into the blood stream to return the previously low calcium levels back to normal.  Once 
this occurs, the calcitriol inactivating enzyme 24-hydroxylase is activated and 
hydroxylates calcitirol on the 24
th
 carbon, which marks it for degradation.  This is the 
feedback mechanism to prevent calcitriol from continuously raising plasma calcium 
levels (1).  An additional feedback mechanism is also in place when calcium levels are 
elevated.  Calcitonin is a 32-amino acid polypeptide hormone produced by parafollicular 
cells in the thyroid that, essentially, counteracts the effects of calcitriol by inhibiting 
calcium absorption in the small intesting, osteoclast activity in the bones, and calcium 
reabsorption in the kidneys to allow calcium to be excreted in the urine (1).  
Suboptimal calcium intakes are common (90) and require a PTH/calcitriol 
response in order to maintain calcium homeostasis.  Our lab (and others) have shown that 
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calcitriol exerts significant effects on adipocyte biology.  Although a classical nuclear 
receptor hormone, calcitriol can also bind to a plasma membrane receptor (1, 25-
MAARs) and cause rapid calcium influx, which typically has a Ca
2+
 concentration of  
~100 nM.  The rapid influx of calcium causes an increase in ROS production by 
inhibiting ROS clearing enzymes, such as superoxide dismutase and glutathione 
peroxidase (91), resulting in a decrease in mitochondrial function,. Furthermore, Ca
2+
 
influx and signaling that occurs in the presence of calcitriol coordinately stimulates fatty 
acid synthase activity and inhibits lipolysis in adipocytes (92-96).  Calcitriol can freely 
diffuse across the plasma membrane and interact with another receptor in the cytosol, the 
nuclear vitamin D receptor (nVDR).  Once calcitriol binds to the nVDR, it is translocated 
to the nucleus where it dimerizes with the retinoid X receptor (RXR) and binds to the 
vitamin D response element (VDRE) where it can initiate the transcription of a plethora 
of genes.  Among these is fatty acid synthase, which is a rate-limiting enzyme in de novo 
lipogenesis (97-99).  It also decreases fatty acid oxidation and key mitochondrial 
metabolizing enzymes and transcription factors, such as PGC1- (100).  Another 
mitochondrial protein that is suppressed with calcitriol treatment of adipocytes is 
uncoupling protein 2 (UCP-2) (100, 101).  UCP-2 helps to dissipate the mitochondrial 
membrane potential by uncoupling oxidative phosphorylation and ATP synthesis (102).  
UCP-2 allows protons to leak back across the mitochondrial inner membrane, which will 
allow for more efficient flow of electrons through the electron transport chain in the 
mitochondria (102).  Since calcitriol decreases UCP-2 expression (103), this will also 
lead to increased ROS production (91) leading to oxidative stress and an increase in pro-
inflammatory cytokine production (104).   
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2.3.5  Leucine Overview: 
 Leucine is an essential amino acid that is a member of the branched-chain amino 
acid (BCAA) family, along with isoleucine and valine. Leucine is abundant in foods that 
are high in protein, as leucine is a building block for proteins.  Some examples of foods 
rich in leucine include the whey fraction of dairy, meats, eggs and soy protein.  Although 
leucine supplementation is primarily thought of to help with building lean muscle mass 
through activation of the mammalian target of rapamycin (mTOR), recent studies have 
shown that leucine can also play a role in energy partitioning and intracellular signaling 
pathways. The section below will describe leucine metabolism and its role in energy 
partitioning and cell signaling pathways. 
 
2.3.6  Leucine Metabolism: 
 Most amino acid metabolism occurs predominantly in the liver, however the liver 
contains relatively low expression levels of hepatic BCAA catabolic enzymes (105).  As 
a result, circulating BCAA levels remain unchanged after passing through the liver and, 
therefore, the plasma and peripheral tissue concentration of BCAAs are highly dependent 
on dietary intake of amino acids (105, 106).  Once ingested, leucine is transaminated to 
-ketoisocaproate (KIC) in a reversible reaction by the mitochondrial enzyme BCAA 
transferase (BCAT), (105); KIC is then capable of entering two metabolic pathways to 
generate either isovaleryl-CoA (90-95% of leucine metabolism) or -hydroxy--
methylbutyrate (HMB; 5-10% of leucine metabolism) (105).  The primary route for KIC 
during leucine metabolism first involves oxidative decarboxylation through the 
mitochondrial branched-chain ketoacid dehydrogenase complex (BCKDH) (105).  The 
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BCKDH complex consists of three enzymes including a branched-chain -keto acid 
decarboxylase (E1), a dihydrolipoyl transacylase (E2) and a dihydrolipoyl dehydrogenase 
(E3).  The activity of the BCKDH is regulated by a BCKDH phosphatase and kinase 
through phosphorylation and dephosphorylation of the E1 subunit, thus capable of 
regulating BCAA metabolism (107) (106). Through a series of reactions, KIC is 
converted to HMG-CoA and ultimately acetyl-CoA and acetoacetate, which can enter 
into the citric acid cycle (105).  Excess KIC can also be released into circulation, taken up 
by other organs such as the liver and adipose tissue, where they can be resynthesized into 
BCAAs or oxidized as fuels to generate ATP (25) (105).  The second possible fate of 
KIC generated from leucine involves conversion to HMB by the enzyme KIC-
dioxygenase (105).  Up to 40% of HMB is excreted in the urine with the remaining HMB 
being converted to HMB-CoA then HMG-CoA (108).  HMG-CoA has multiple fates as 
well:  1.  interconversion to MG-CoA and back to HMB-CoA; 2.  Conversion to 
acetoacetyl-CoA and acetyl-CoA, or 3.  conversion to mevalonate by HMG-CoA 
reductase to eventually yield cholesterol (108).  Figure 2-2 summarizes this process. 
 
2.3.7  Sirtuin Signaling: 
 Sirtuins are a member of the class III histone deacylases that consume one 
molecule of nicotinamide adenine dinucleotide (NAD
+
) with each deacylation cycle 
(109).  The first sirtuin protein was identified in Saccharomyces cerevisiae as silent 
information regulator 2 (SIR2) (110).  It was later demonstrated that SIR2 extended the 
replicative lifespan of yeast (111, 112), and this model was further expanded to 
Caenorhabditis elegans (113, 114) and Drosophila melanogaster (115) and to mediate 
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beneficial effects of calorie restriction (CR) on health and longevity (115-118).  More 
recent studies in many organisms have now confirmed the original hypothesis that 
sirtuins are conserved, diet-sensitive, anti-aging proteins.  The sections below will 
describe the relevant forms of the sirtuin proteins, their corresponding signaling cascade, 
and the role leucine plays in this process. 
 There are seven known mammalian sirtuins, SIRT1-7, which function to regulate 
metabolism in various ways in many tissues (119).  SIRT1, SIRT6 and SIRT7 are 
localized in the nucleus, where they are involved in deacetylation of histones to influence 
gene expression epigenetically (120).  SIRT2 was originally thought of as a cytosolic 
sirtuin, however recent studies show that SIRT2 is also found in the nucleus where if 
functions to modulate cell cycle control (121-123).  SIRT3-5 are localized in the 
mitochondria, where they function to regulate the activities of metabolic enzymes and 
moderate oxidative stress by switching cells to favor mitochondrial oxidative metabolism 
(124).  This report will focus primarily on SIRT1, the most highly studied sirtuin, as well 
as SIRT3 and its role in modulating oxidative stress. 
 During times of fasting or CR, blood glucose levels decrease causing hepatic 
metabolism to immediately shift to glycogen breakdown and then gluconeogenesis to 
ensure glucose supply and ketone body production to bridge periods of energy deficits.  
Additionally, fasting also activates muscle and liver oxidation of fatty acids produced by 
lipolysis in white adipose tissue.  Multiple transcription factors are involved in this switch 
to adapt to the energy deprivation, and SIRT1 mediates the metabolic switch during 
fasting (125).  In the initial phase of fasting, pancreatic alpha cells produce glucagon to 
activate hepatic gluconeogenesis through the cyclic AMP response-element-binding 
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protein (CREB) and its coactivator, CREB-regulated transcription coactivator 2 
(CRTC2).  However, during periods of extended fasting this effect is cancelled by 
SIRT1-mediated CRTC2 deacetylation and, thus, targeting the coactivator for 
ubiquitin/proteasome-mediated destruction (125).  Next, SIRT1 deacetylates and 
activates PGC-1, a coactivator for forkhead box O1 (FOXO1), which is also important 
for stimulating mitochondrial biogenesis to assist the liver in accommodating the reduced 
energy status (126).  In order to increase energy production, SIRT1 can stimulate fatty 
acid oxidation by deacetylating and activating the nuclear receptor, PPAR (127).  
SIRT1 can also stop the production of energy from glycolysis by deacetylating and 
repressing glycolytic enzymes such as phosphoglycerate mutase-1 (PGAM-1) (128).   
 In addition to glucose homeostasis, the liver also plays important roles in 
regulating lipid and cholesterol homeostasis (119).  During fasting, fat and cholesterol 
synthesis in the liver is turned off, and lipolysis in WAT is favored (119).  The primary 
hepatic transcription factors for lipogenesis and cholesterol synthesis are proteins 
belonging to the sterol regulatory element binding protein (SREBP) family (129).  SIRT1 
deacetylates SREBP1, targeting the protein for destruction through the ubiquitin-
proteasome system, and ultimately results in repression of fat and cholesterol synthesis 
(130).   
 During fasting or CR, the body switches from carbohydrate to lipid use for energy 
production and this effect is mediated, in part, via SIRT1 deacetylation and activation of 
PGC-1 (131). AMPK is also activated by energy depletion, causing an increase in 
cellular AMP levels and, thus, can also drive the expression of the PGC-1 gene under 
these conditions (132).  In order to be fully activated, PGC-1 can be phosphorylated by 
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AMPK and deacetylated by SIRT1 (133). This ultimately results in increased 
mitochondrial biogenesis and fatty acid oxidation in the muscle (134).  Interestingly, the 
effect of SIRT1 and AMPK can also be amplified through a reciprocal positive regulatory 
loop.  AMPK can increase NAD
+
 levels by upregulating nicotinamide 
phosphoribosyltransferase (NAMPT) (135, 136), which is one of the crucial enzymes for 
NAD biosynthesis.  On the other hand, SIRT1 can deacetylate the serine/threonine kinase 
liver kinase B1 (LKB1) to activate AMPK (137).   
 Sirtuins also play a crucial role in WAT, where they can act with secreted 
adipokines, specifically adiponectin (63). During exercise, the muscle adiponectin 
receptor is activated and induces expression of SIRT1, AMPK, and PGC-1 in a Ca
2+
-
dependent manner (63).  This, in turn, stimulates fatty acid oxidation and mitochondrial 
biogenesis (63).  Furthermore, SIRT1 can promote fat mobilization from WAT to support 
lipid oxidation in the liver and muscle (138).  SIRT1 can also deacetylate two critical 
lysine residues on PPAR, resulting in a white adipocyte switch into the metabolically 
active brown fat (139).  SIRT1 is also capable of inhibiting NF-B signaling, thereby 
reducing inflammatory stress (140-142).  In summary, SIRT1 has multiple beneficial 
effects on skeletal muscle, liver and adipocytes during exercise or a caloric restricted 
state to promote fatty acid oxidation, and these events are the result of cumulative effects 
of adiponectin/SIRT1/AMPK signaling. 
 In addition to the nuclear sirtuin (SIRT1), mitochondrial SIRT3 is critical in fatty 
acid oxidation in the mitochondria (119).  SIRT3 has been shown to be a downstream 
target of PGC-1 and plays an important role in the suppression of ROS through PGC-
1-dependent induction of ROS-detoxifying enzymes and several components of the 
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respiratory chain, including glutathione peroxidase-1, superoxide dismutase-2, ATP 
synthase 5c, and cytochrome c (133).  During fasting or CR, SIRT3 protein level and 
activity are upregulated in the mitochondria to promote lipid catabolism and fatty acid 
oxidation by deacetylating long-chain-specific acyl coenzyme A dehydrogenase (LCAD) 
(134).  Therefore, it appears that SIRT1/SIRT3/AMPK are a part of a signaling pathway 
that can provide beneficial effects for oxidizing fat and reducing oxidative and 
inflammatory stress.  Multiple studies have confirmed that in addition to resveratrol 
(143), leucine is a stimulator of the sirtuin pathway(144-147).  These studies will be 
discussed in detail below. 
 
2.3.8  Effects of Leucine in Muscle and Fat: 
 Perhaps the most well-known attribute of leucine is its potential effect on 
promoting muscle protein synthesis during periods of fasting, caloric restriction, or 
exercise (148).  Supplementation with leucine alone or in combination with other BCAAs 
(isoleucine and valine) stimulates muscle protein synthesis in both rodent and human 
model systems (149-151).  The leucine-induced muscle protein synthesis occurs by 
targeting the mammalian target of rapamycin pathway (mTOR), a Ser/Thr kinase (152).  
Studies have shown that leucine activates mTOR kinase and promotes the 
phosphorylation of eukaryotic initiation factor 4 complex causing dissociation from its 
binding protein and activation of eIF4E.  Activated mTOR results in downstream 
activation of p70S6 kinase and phosphorylase S6 ribosomal proteins (153).  Furthermore, 
leucine can also activate a second initiation factor, eukaryotic initiation factor-4G 
(eIF4G) in an mTOR-independent manner (153).  Overall, leucine supplementation 
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induces the activation of multiple transcriptional factors, causing the promotion of protein 
translation and synthesis (152, 153).   
 Leucine also has beneficial effects regarding mitochondrial metabolism and 
inflammatory cytokine production.  For example, leucine treatment (0.5 mM) increases 
mitochondrial UCP2 expression and adiponectin production in differentiated 3T3-L1 
adipocytes (154).  Leucine also promoted fatty acid oxidation in C2C12 murine muscle 
cells (154).  The effects of leucine on fatty acid oxidation and are presumably due to 
direct effects of mitochondrial biogenesis, as leucine treatment increases mitochondrial 
mass by 30% and 53% in C2C12 myocytes and 3T3-L1 adipocytes, respectively (147). 
Furthermore, leucine is capable of activating SIRT1 in a cell free system (144) as well as 
in both adipocytes and muscle cells (146, 147).   For example, leucine stimulated 
mitochondrial biogenesis genes SIRT1, PGC-1 and NRF-1 as well as mitochondrial 
component genes UCP3, COX, and NADH expression by 3-5 fold in C2C12 cells (147).  
Knockdown of SIRT1 resulted in suppression of leucine-induced stimulation of PGC-1 
and NRF-1, indicating that SIRT1 mediates leucine induced mitochondrial biogenesis in 
muscle cells (147).  Consistent with these observations, leucine has been found to 
markedly enhance oxidative capacity and increase mitochondrial density in skeletal 
muscle, partially through AMPK-mediated increases of PGC-1 (155).  A more recent 
study indicates that synergy between leucine/HMB and a six-carbon ring structure bound 
to a carboxylic group seem to be a necessary element for leucine/HMB synergy with 
other stilbenes and hydroxycinnamic acids to stimulate AMPK/SIRT1 dependent fatty 
acid oxidation (145).  Six-carbon ring structures, such as pyridoxal phosphate, have been 
shown to inhibit Ca
2+
 influx in vitro (156), resulting in significant decreases in fatty acid 
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synthase expression and activity and corresponding reductions in adipocyte triglyceride 
content (156), because Ca
2+
 signaling coordinately stimulates fatty acid synthase activity 
and inhibits lipolysis in adipocytes (92-96).  In further support, recent studies have shown 
that leucine and its metabolite -hydroxy--methylbutyrate (HMB) activate AMPK 
synergistically with resveratrol and metformin, resulting in increased fatty acid oxidation, 
AMPK activation, SIRT1 and SIRT3 activity in murine muscle cells (146). 
 The beneficial effects of leucine regarding energy partitioning and oxidative 
metabolism can further be expanded to in vivo models of mice and humans (146, 156, 
157).  Bruckbauer et al. recently demonstrated that 6 week feeding of low-dose 
resveratrol combined with either leucine or its metabolite HMB to diet-induced obese 
mice resulted in increased adipose SIRT1 activity, muscle glucose and palmitate uptake 
(via PET/CT), insulin sensitivity (HOMA-IR), improved inflammatory stress biomarkers 
(CRP, IL-6, MCP-1, adiponectin), and reduced adiposity, while low-dose resveratrol 
exerted no independent effects, suggesting leucine or HMB can act synergistically with 
low-dose resveratrol to exert SIRT1-dependent outcomes (146).  In two separate 24 
week, placebo-controlled, randomized trials (one with weight maintenance and one 
hypocaloric diets) in human obese subjects consuming 2.25 g leucine combined with 30 
mg vitamin B6, the supplement resulted in fat loss at both 12 and 24 week time points in 
the weight maintenance group study, while the hypocaloric group study lost up to twice 
as much weight and fat compared to the placebo group (157).  In summary, dairy 
products are rich in both leucine and Ca
2+
.  Leucine promotes mitochondrial biogenesis, 
fatty acid oxidation, and adiponectin production through AMPK/SIRT1/SIRT3 mediated 
mechanisms, while also reducing ROS, and pro-inflammatory cytokine production.  On 
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the other hand, Ca
2+
 inhibits the production of calcitriol.  Calcitriol causes rapid Ca
2+
 
influx and activation of nVDR gene expression resulting in increases in lipogenesis 
through increased fatty acid synthase activity, ROS production, and pro-inflammatory 
cytokine production with reductions in adiponectin production.  Therefore, this 
information provides a strong framework for providing leucine and Ca
2+
 in the form of 
dairy to support weight loss and reduce the oxidative and inflammatory stress associated 
with obesity. 
 
2.4.0  Cellular Microvesicles Overview: 
 Microvesicles are a collective term that refers to small, insoluble factors that are 
generated from most, if not all, eukaryotic cells, and they have gained a high level of 
interest among researchers in recent years due to their role in intracellular 
communication.  Microvesicles are small vesicles ranging from 50 nm up to 3 m in 
diameter, which are released from the origin cell type under normal physiological 
conditions.  In general, there are three types of vesicles:  apoptotic bodies ranging from 
500 nm-3 m in diameter (158), microvesicles (100 nm-1 m) (159), which directly bud 
from the plasma membrane, and nanovesicles (30-100 nm), which include exosomes 
released via exocytosis from mutlivesicular bodies of the endosome (160) (Figure 2-3).   
The properties of cellular vesicles have been reviewed extensively (41, 160-167).  
Briefly, these vesicles have been shown to carry diverse membrane and cytosolic proteins 
as well as messenger and microRNAs (miRNAs) (160-162).  These factors can affect the 
physiology of their target cells in various ways.  For example, they can induce 
intracellular signaling following binding to receptors, or they can confer new properties 
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after the acquisition of new receptors, enzymes, or genetic material by fusion or 
endocytosis (160-162).  Furthermore, they participate in physiological processes 
including hemostasis and thrombosis, inflammation, immune interactions, and 
angiogenesis (162, 168).  Studies have shown elevated levels of microvesicles in blood 
circulation in various disorders, including atherosclerosis and coronary heart disease, pre-
eclampsia, hematological and inflammatory diseases, diabetes, and cancer (162).  
Therefore, microvesicles may be useful as prognostic and diagnostic biomarkers for early 
detection of a wide variety of diseases and could also have a potential role in monitoring 
the treatment of these diseases.  The sections below will review common nomenclature, 
sources of these vesicles, and some standardized isolation and analysis techniques for 
studying microvesicles. 
 
2.4.1  Extracellular Vesicle Nomenclature: 
 Extracellular vesicles (EVs), which include both exosomes and microvesicles, are 
heterogeneous, membranous, cell-derived vesicles approximately 40-5000 nm in 
diameter that are released by a variety of cells into their microenvironment (169-172).  
The terminologies used for addressing EVs have significantly changed over the last 10 
years.  Initially, isolated EVs were named based on their sample source where they were 
derived and based on their size (163, 172).  Some of these names include oncosomes 
(exosomes derived from tumor cells), exosome-like vesicles, microparticles, apoptotic 
bodies, exosomes, prostasomes, nanoparticles, microvesicles, and shedding microvesicles 
(172).  The confusion in the variously used terminologies has caused ambiguity in 
isolation methods and data reporting.  For example, exosomes have classically been 
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defined as originating from the endosomal compartment by fusion of multivesicular 
bodies with plasma membrane, whereas microvesicles, ectosomes or shed 
vesicles/particles have been thought to originate by direct budding from the plasma 
membrane (163, 167).  The literature describes exosomes as smaller than 100 nm in 
diameter, while microvesicles are considered larger than 100 nm in diameter (162, 166, 
167).  However, this strict definition to separate the two types of vesicles based on size 
and origin has not definitively been established (173-175), and there is currently no 
consensus on markers that distinguish the origin of these vesicles once they have left the 
cell (175).  For example, there is little evidence that particles less than 100 nm in 
diameter cannot bud from the plasma membrane, and likewise, vesicles containing 
exosome-like markers are not always smaller than 100 nm (176).  Therefore, for the 
purposes of this review the term “microvesicles” will be used to describe both exosome-
like vesicles and vesicles that have bud from the plasma membrane.   
 
2.4.2 Microvesicle Methodology Overview: 
 Microvesicles have garnered significant attention because of the specific 
mechanisms for their release from cells, their involvement in cell-to-cell signaling, and 
their utility as potential markers of disease (166, 176-187).  In the midst of growing 
interest in microvesicles, technical standardization is of central importance due to the 
multitude of possible isolation and analyzing techniques available (176).  The sections 
below will describe the various isolation techniques and analysis technologies currently 
used to study microvesicles. 
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2.4.2.1  Isolation Methods – Differential Centrifugation: 
 Microvesicles have been successfully isolated from cell culture conditioned media 
(188), and various body fluids including plasma (189, 190), serum (189), saliva (190), 
amniotic fluid (191, 192), breast milk (190), urine (193, 194), pleural effusions (195), 
ocular effluent and aqueous humor (196), ascites (197), semen (198), nasal secretions 
(199), cerebrospinal fluid (200), bronchoalveolar lavage (201), synovial fluid (202), and 
bile (203).  The gold standard and most commonly used protocol for microvesicle 
isolation/purification is differential centrifugation (172).  However, this depends on the 
biological fluid the microvesicles are being isolated from, as the various biological fluids 
have different viscosities and, therefore, require different speeds and centrifugation times 
to acquire the appropriate vesicles (171, 172, 188).  Although various protocols are 
available, differential centrifugation typically begins with a low speed spin at 
approximately 300 x g for ten minutes to eliminate dead cells and bulky apoptotic debris 
(171, 172, 188).  The supernatant is then centrifuged in a second step to eliminate larger 
vesicles and debris, typically anywhere from 1,000-20,000 x g.  The slower the spin 
(closer to 1000 x g), the more plasma membrane budding vesicles will be present in the 
sample, whereas the faster spin (closer to 20,000 x g) will eliminate/pellet these vesicles, 
leaving the smaller exosome-like vesicles in the supernatant (176).  The remaining 
supernatant is subjected to a final, high-speed spin step at approximately 100,000 x g for 
1-8 hours (172).  This step typically takes place at 4C, but can vary depending on the 
specific protocol (172).  Once the high-speed centrifugation step occurs, the 
microvesicles will be pelleted and can then be resuspended in a solution, typically 
phosphate buffered saline (PBS), for analysis (171, 172, 188).  For a more purified 
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microvesicle sample and to eliminate contaminants, the pellet can be washed again in a 
large volume of PBS and centrifuged one last time at 100,000 x g, however this results in 
a relatively low recovery of microvesicles ranging from 5-25% of the starting 
microvesicle MHC class II concentration (171, 172, 176, 204).  An additional way to use 
centrifugation to separate vesicles is to use a sucrose gradient, which separates vesicles 
based on their different flotation densities.  Exosomes have a flotation density of 1.08-
1.22 g/mL on sucrose gradients (205), while vesicles purified from the endoplasmic 
reticulum float at 1.18-1.25 g/mL and vesicles from the golgi at 1.05-1.12 g/mL (188). 
 
2.4.2.2  Isolation Methods – Microfiltration: 
A second method used to separate microvesicles based on their size is 
microfiltration technologies.  Essentially, the biological fluid is applied to a filtration 
apparatus containing a membrane with a specific pore sizes that will prevent a specific 
sized vesicle from passing through while allowing smaller vesicles to pass.  Although 
filtration techniques by themselves have only been recently introduced, many differential 
centrifugation protocols apply initial microfiltration steps rather than the initial low speed 
spins described above (172).  For example, a biological fluid could initially be filtered 
through a 1 m filter to eliminate dead cells and larger cell debris followed by an 
ultracentrifugation spin at 100,000 x g.  Although filtration technologies are improving, 
they face several challenges, such as co-purifying abundant proteins with microvesicle 
isolation, contamination of isolated microvesicles with components of the filtration 
membrane and trapping of microvesicles into nano- or micro-pores (172).  Thus, isolation 
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conditions, such as the membrane material and pore size, must be optimized for maximal 
recovery of microvesicles and a more pure enrichment (170-172). 
 
2.4.2.3  Isolation Methods – Antibody-Coated Magnetic Beads: 
 A third isolation method involves using magnetic beads that are coated with an 
antibody specific to a protein present on the microvesicle. Proteomic studies 
characterizing the molecular composition of microvesicles have revealed the presence of 
both ubiquitous and cell-specific proteins that can be used as markers for microvesicles 
(206).  Therefore, an antibody for the protein of interest is coated on magnetic beads and 
the beads are incubated with the biological fluid for a period of time.  Afterwards, a 
magnet is applied to the sample to retain the beads, which will be bound to the 
microvesicle via the antibody-protein complex (176).  This method is quick and useful 
for isolating a specific sub-population of microvesicle.  However, this method requires 
initial proteomic analysis to reveal a specific protein present on the microvesicle 
population of interest and, therefore, presents a problem with samples of unknown 
proteins.  Furthermore, this method is not intended for isolation of large amounts of 
microvesicles (172).  In this case, it is suggested that pre-concentration of samples and 
prior centrifugations should be considered to reduce the sample volume. 
 A similar technology called microfluidics has also been shown to be an effective 
method to isolate microvesicles containing a specific surface protein (176).  This 
technology involves perfusing the biological fluid across an antibody-coated surface to 
capture exosomes or microvesicles.  In a recent 2010 study by Chen et al., rapid recovery 
of small microvesicles was demonstrated using serum and conditioned culture medium 
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(207).  As with antibody coated magnetic beads, microfluidics will only capture 
microvesicles that present a specific surface protein, thus making total microvesicle 
isolation not applicable (172, 176, 206). 
 
2.4.2.4  Isolation Methods – Precipitation Techniques: 
 Many biotechnology companies are producing kits that will quickly and easily 
isolate microvesicles from biological fluids using a polymeric based precipitation 
methods.  For example, the ExoQuick kits (System Biosciences, CA, USA) are 
designed to precipitate exosomes from various fluids (urine, plasma, serum, and tissue 
culture media) through an overnight incubation period, followed by a simple spin to 
pellet the exosomes for further analysis (208).  Drawbacks include the tendency of 
polymer-based precipitation methods to include numerous non-microvesicle 
contaminants such as lipoproteins (176).  In a recent study, Yamada et al. demonstrated 
the highest yield of microvesicles was achieved using ultracentrifugation with 
ExoQuick precipitation, whereas higher quality microvesicle isolation with intact 
morphological structures was achieved through ultracentrifugation with density gradient 
centrifugation (209).   
 
2.4.3.0  Investigative Technologies: 
 Due to the small size, heterogeneity, and unknown surface markers, microvesicle 
research is held back by the currently available technologies (210).  Although traditional 
methods, such as western blotting, are often used to analyze microvesicle protein content, 
these methods lack the ability to investigate the microvesicles while they are in their 
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unaltered physiological state (211).  Current research is geared towards understanding the 
size, concentration and proteomic/genomic profile of microvesicles as well as their 
application to functional aspects in biological processes (211).  The various analysis 
methods currently available have both positive and negative aspects, and the sections 
below will discuss those aspects in detail. 
 
2.4.3.1  Investigative Technologies – Electron Microscopy: 
 Electron microscopy (EM) techniques have been well established for many 
decades, and the application of this technique towards microvesicle research has been 
shown to be very useful by providing direct evidence for the presence of vesicular 
structures (205).  Furthermore, the use of heavy metal stains such as osmium tetroxide 
and uranyl acetate in transmission electron microscopy (TEM) allows for the recognition 
of membrane-surrounded vesicles (212).  The most common techniques involve applying 
concentrated microvesicle suspensions to grids and fixing them with paraformaldehyde, 
or fixing the pelleted microvesicles and generating ultra-thin sections of the pellet for 
analysis on a TEM (212).  Although using a suspension of microvesicles would be 
simpler to work with, the concentration of microvesicles will be lower, thus producing 
fewer vesicles per field of view.  TEM can be combined with immunoglobulins 
conjugated with nanogold particles to target a specific marker of interest, providing the 
ability to see detailed images and specific location for a protein of interest.  Other types 
of EM, such as scanning EM (SEM) or cryo-EM are often used (213, 214).  Cryo-EM 
allows for analyzing frozen samples and avoids the various dehydration and chemical 
fixatives associated with SEM that could alter the microvesicle state (215).  In 
 42 
conclusion, EM techniques are valuable for determining size, morphology and specificity 
of microvesicles, but EM is not quantitative and it lacks the ability to assess 
concentration. 
 
2.4.3.2  Investigative Technologies – Capture ELISA: 
 Capture, or sandwich enzyme-linked immunosorbent assay (ELISA) is a common 
biochemical technique that involves coating a 96-well plate surface with an antibody 
specific to an antigen of interest.  The sample is added to the plate, which will bind the 
antigen to the antibody.  Then a detecting antibody is added to the plate to bind to the 
antigen, followed by an enzyme-linked secondary antibody.  A substrate is then added to 
the plate and the enzyme will convert the substrate to a fluorescent or colormetric version 
that can be detected by a plate reader.  Combined with a standard curve of known antigen 
concentration, this method allows for the indirect calculation of an antigen present in the 
sample.  Although this method is advantageous for determining antigen concentration, 
capture ELISA cannot discriminate between the various sized microvesicles or between 
microvesicle-associated versus free antigen (211). 
 
2.4.3.3  Investigative Technologies – Dynamic Light Scattering: 
 Dynamic light scattering (DLS) is a technique used to determine the average 
particle size in a fluid suspension by shining a laser into the sample and measuring the 
light scatter (213, 216, 217).  This measurement is determined by the particle core size, 
the size of surface structures, particle concentration, and the types of ions present in the 
medium.  Since the output data from this technique is a mean particle size, DLS is 
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advantageous for determining microvesicle concentration in a mono-disperse sample 
(176, 211).  However, microvesicles are heterogeneous in size and, therefore, DLS 
cannot discriminate among the polydisperse sample (211).   
 
2.4.3.4  Investigative Technologies – Flow Cytometry: 
 Flow cytometry is an extremely powerful method for both the qualitative and 
quantitative characterization of a large number of cells and smaller vesicles (176, 211).  
Cells or vesicles in suspension are passed through a chamber containing a laser and 
various detectors that can measure cell size (forward scatter), cell granularity (side 
scatter), or various wavelengths of fluorescent filters (fluorescent intensity).  Antibodies 
conjugated with a fluorphore can be added to the sample to allow for the 
detection/measurement of a specific antigen.  Furthermore, the application of Megamix 
bead gating, which utilizes a synthetic bead mixture of known size and concentration, can 
allow the investigator to calculate concentration and size of the cells or particles (218, 
219).  Therefore, flow cytometry is a useful technique to determine concentration and 
specificity.  However, most conventional flow cytometers do not detect vesicles smaller 
than 500 nm, which will only allow for the anlaysis of larger microvesicles and 
completely excludes exosomes (176, 218, 219).  Newer instruments, such as the Gallios 
(Beckman Coulter), BD-Influx (Becton Dickenson) and Apogee (Apogee Flow Systems) 
claim the ability to discriminate between particles as small as 200 nm (220).  However, 
these claims are determined using polystyrene beads with a higher refractive index 
compared to the microvesicles (221), which has been the subject of multiple discussions 
regarding the standardization of the technology.  Furthermore, typical light-scattering 
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methods (forward and side scattering) can be confounded by protein aggregates, and a 
term known as the “swarm” effect (222).  Essentially, the “swarm” effect involves the 
detection of multiple small microvesicles as one single light scattering event and, 
therefore will significantly alter the calculation of microvesicle concentration (222).  In 
conclusion, flow cytometry can be advantageous for analyzing concentration, size and 
specificity of microvesicles >500 nm, however it excludes the ability to analyze the 
exosome fraction of microvesicles. 
 
2.4.3.5  Investigative Technologies – Nanoparticle Tracking Analysis: 
 Nanoparticle tracking analysis (NTA) is a recently developed technology that 
allows for direct, real-time visualization and analysis of nanoparticles in liquids that 
overcomes many of the problems associated with the previously described methods (170, 
171, 211, 213, 216, 217).  NTA relates the rate of Brownian motion to particle size 
through the use of a light microscope and video camera (211, 217).  The vesicles are 
visualized by light scattering with the light microscope, and a video is taken for 30 
seconds to one minute (depending on the concentration and heterogeneity of the sample) 
(211, 217).  The software then tracks each individual particle’s Brownian motion and the 
velocity of particle movement is used to calculate particle size by applying the two-
dimensional Stokes-Einstein equation to solve for particle diameter, thus generating a 
histogram of particle size versus concentration (211, 217).  This technology has been 
further developed to utilize fluorescent markers to determine antigen specificity in 
combination with particle size and concentration, allowing for the ability to determine a 
percentage of the total microvesicle population expressing an antigen of interest (223).  
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Although NTA can analyze particles as large as 1 m (Brownian motion is to slow to 
measure above this size), the large number of small vesicles in these preparations requires 
that the sample be diluted for analysis, thus significantly reducing the larger particles and, 
therefore, underestimating their concentration (224, 225).  Thus, analysis of larger 
vesicles (>500 nm) may be better carried out on a flow cytometer.  In conclusion, NTA 
technology overcomes most of the issues associated with the techniques mentioned above 
and is considered the gold standard for exosome and microvesicle research (223, 224).  
However, the optimization and standardization can be extensive, depending on the 
preparation methods.    
 
2.4.4  Adipocyte Derived Microvesicles - Protein: 
 Like other eukaryotic cell types, multiple studies have shown that adipocytes 
release microvesicles containing a variety of proteins and miRNAs, and these 
microvesicles have been termed adipocyte derived microvesicles (ADMs) (41, 164, 206, 
226-230).  One of the first studies that investigated ADMs was by Aoki et al., where they 
characterized the protein composition of ADMs secreted from the adipocyte cell line 
3T3-L1 (226).  Aoki et al. found that 3T3-L1 cells secreted milk fat globule-epidermal 
growth factor 8 (MFG-E8) associated microvesicles, and they displayed a heterogeneous 
mixture of exosome-like and larger membrane vesicles as shown by electron microscopy 
(226).  Furthermore, proteomic and biochemical analysis revealed that the microvesicles 
with exosomal features contained a variety of secreted, integral, cytosolic and nuclear 
proteins (226).   
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Of particular interest, Aoki et al. and others have demonstrated that adiponectin 
was associated with the ADM fraction, and the HMW form was the most abundant form 
present in the ADMs (226, 231, 232).  Sano et al. isolated ADMs from differentiated 
3T3-L1 cell culture supernatants and demonstrated that ADMs isolated from cells 
cultured under hypoxic conditions are enriched in enzymes related to lipogenesis (acetyl-
CoA carboxylase, glucose-6-phosphate dehydrogenase, fatty acid synthase) and promote 
lipid accumulation in recipient 3T3-L1 adipocytes (232).  In a recent study from 
Poonsawat et al., ADMs isolated from mouse serum contained HMW adiopnectin and 
trace amounts of resistin, but not leptin (231), confirming not only that ADMs can reach 
systemic circulation, but also that adiponectin can be used as a marker for circulating 
ADMs.   
Other groups have provided evidence that stimulus-induced lipid synthesis 
between differently sized adipocytes is controlled by the release of microvesicle-
associated CD73 from large cells and its subsequent translocation to LD of small cells 
(164, 229, 230).  This information transfer via microvesicles harboring the 
glycosylphosphatidylinositol (GPI) anchored proteins may shift the burden of TAG 
storage from large to small adipocytes (164, 230).  Therefore, it is likely that ADMs may 
mediate intercellular communication between adipose, vascular tissue, and systemic 
circulation. 
 
2.4.5  ADM miRNA Expression: 
 MicroRNAs (miRNA) are highly conserved noncoding RNA molecules of 
approximately 22 nucleotides long that are capable of exerting post-transcriptional effects 
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on gene expression (41).  These miRNAs generally bind to the target sequence localized 
in the 3’-untranslated region of their target mRNA and regulate protein translation or 
mRNA stability (233, 234).  Early studies in Caenorhabditis elegans determined that 
miRNA-mediated regulation was at the post-transcriptional level, because large effects 
were observed on protein expression and no effects on mRNA abundance (235).  In other 
biological systems, modest effects on the amounts of the mRNA target were seen in 
addition to substantial degrees of regulation at the protein level (236).  Therefore, 
miRNAs are expressed in a tissue and cell type specific manner and they have been 
shown to play an essential role in multiple biological processes such as proliferation, 
apoptosis, development, and differentiation (41). 
 In obese individuals, miRNAs are capable of regulating adipocyte differentiation, 
oxidative stress, inflammation, and angiogenesis in the adipose tissue (41, 237).  
Specifically, the miRNA-17-92 cluster, miRNA-21, miRNA-103, miRNA-143, miRNA-
371, and miRNA-378/378* have been shown to increase adipogenesis through the up-
regulation of adipogenic markers and by increased triglycerides (238-242).  The miRNA-
17-92 cluster can accelerate adipocyte differentiation by negatively regulating the key 
cell cycle regulator and tumor suppressor Rb2/p130 (241).  MiRNA-21 can inhibit the 
TGF- signaling pathway, which is known to inhibit adipogenesis (240, 243), and mi-143 
increases adipogenesis through down-regulating ERK-5 (240).  MiRNA-103 and 
miRNA-143 are also capable of inhibiting multiple targets in pathways that involve 
cellular acetyl-CoA and lipid metabolism, and several antiadipogenic factors, such as aryl 
hydrocarbon receptor nuclear translocator (ARNT), frizzled homolog 1 (FZD-1), and 
runt-related transcription factor 1 (RUNX1T1/ETO/MTG8) (242).  MiRNA-371 
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stimulates expression of adiponectin and fatty acid binding protein 4 (FABP-4) (238) and 
miRNA378/378* specifically increases transcriptional activity of C/EBP and C/EBP 
on adipocyte gene promoters and also increases transactivation of the glucose transporter 
type 4 (GLUT4) promoter by C/EBP (239). 
 Conversely, multiple miRNAs can inhibit the adipogenic differentiation program, 
such as let-7, miRNA-27, miRNA-130, miRNA-138, miRNA-369-5p, and miRNA-448, 
through down-regulation of adipogenic factors and through a decrease in triglyceride 
uptake and storage (238, 244-248).  Specifically, let-7 has been shown to inhibit 
adipogenesis by inhibiting high-mobility group AT-hook 2 (HMGA-2) (247); miRNA-27 
and miRNA-130 by directly inhibiting PPAR (245, 249, 250); miRNA-138 by inhibiting 
the nuclear receptor coregulator adenovirus early region 1-A (E1A)-like inhibitor of 
differentiation 1 (EID-1) (248); miRNA-369-5b by reducing adiponectin and FABP-4 
(238); miRNA-448 by reducing the expression of Kruppel-lick factor (KLF-5) (244).  A 
list of disregulated miRNAs in adipose and vascular tissue is available (251) 
 Impairment of adipocyte function is also associated with endoplasmic reticulum 
and mitochondrial oxidative stress, which further exacerbates adipose tissue dysfunction 
(251).  Dysfunctional adipocytes, such as those in obese adipose tissue, exhibit an 
inflammatory phenotype, with increased production of pro-inflammatory cytokines and 
decreased production of anti-inflammatory cytokines (251-253).  Of particular interest, 
miRNA221 and 222 correlate positively with TNF- and negatively with adiponectin 
(254), while miRNA-132 contributes to the inflammatory phenotype and macrophage 
accumulation by activating the inflammatory NF-B pathway in adipocytes to stimulate 
chemokine production (255).  MiRNA-221 and -222 also inhibit endothelial cell 
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migration, proliferation, and angiogenesis, which contribute to hypoxia (256).  Hypoxia 
can induce inflammatory cytokine production in adipocytes and causes increases in 
miRNA27 in adipose tissue of obese mice, therefore, leading to impaired adipogenesis 
and contributing to the development of obesity-related insulin resistance and type 2 
diabetes (246, 251).  Specifically, miRNA-29a/b/c expression is increased in muscle, 
liver, and adipose tissue of diabetic rats, leading to insulin resistance in adipocytes (257).  
Furthermore, miRNA-320 increases insulin sensitivity by improving insulin-PI3K 
signaling pathways (258).   
 Recent evidence indicates that microvesicles are enriched in both RNAs and 
miRNAs, and these RNAs can be taken up by resident macrophages, which can 
potentially enter circulation (259).  Furthermore, cells can selectively package miRNAs 
into microvesicles and actively secrete them into the blood, where they can actively travel 
to distant tissues in the body for communication purposes (237, 259).  For example, IL-
1 has been shown to be secreted/released from monocytes/macrophages via 5 different 
mechanisms:  exocytosis of IL-1-containing secretory lysosomes, release of IL-1 from 
shed plasma membrane microvesicles, fusion of multivesicular bodies with the plasma 
membrane and subsequent release of IL-1 containing exosomes, export of IL-1 
through the plasma membrane using specific membrane transporters, and release of IL-1 
on cell lysis (260).   
 In a recent study, 71 miRNAs were found to be coexpressed in microvesicles in 
plasma and peripheral blood monocytes (261).  The majority of these miRNAs were 
involved in regulating cellular differentiation of blood cells, metabolic pathways and 
immune function (261).  Therefore, it is possible that miRNA levels in microvesicles in 
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plasma mirror specific pathological processes in peripheral blood monocytes, vascular 
and adipose tissue, which could provide insight into the metabolic disease state in a non-
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Figure 2-3:  Generation of cellular microvesicles via membrane shedding (top) and 























Effects of Calcitriol, Leucine and Dairy Products On Monocyte – 



















3.1  Abstract: 
We previously demonstrated that 1,25-Dihydroxycholecalciferol (calcitriol) and 
leucine have the ability to modulate adipocyte and macrophage inflammatory cytokine 
production. Since several of these affected cytokines are also involved in endothelial cell 
adhesion and infiltration by monocytes, we sought to determine if calcitriol and leucine 
treatment of adipocytes could cause functional effects on this inflammatory process.  
3T3-L1 adipocytes were treated with vehicle, calcitriol, leucine or both for 48 hr and 
conditioned medium (CM) was collected and incubated with fluorescently labeled U937 
monocytic cells while being perfused across a monolayer of EA hy.926 endothelial cells.  
Compared to vehicle, calcitriol treatment resulted in a 3.47  0.39 fold increase in the 
monocyte to endothelial cell ratio (M:E), while leucine (0.61  0.07 fold decrease) and 
the combined treatments (0.81  0.02 fold decrease) had the opposite effect.  This same 
trend was observed for both CD11b and CD54 expression on U937 and EA hy.926 cells, 
respectively. The adhesion assay was also applied using an ex vivo design in which 
human plasma was taken at baseline, day 7, and day 84 from obese individuals that 
consumed either high (>3.5 servings/d) or low (<0.5 servings/d) dairy diets for 12 weeks.  
Plasma from the high dairy group significantly decreased U937 adhesion to the EA 
hy.926 monolayer, while plasma from the low dairy group had the opposite effect.  Data 
from this study suggests dairy products, via calcitriol suppression and high leucine 





3.2  Introduction: 
 Adipose tissue is a significant source of both reactive oxygen species (ROS) and 
inflammatory cytokines (1, 2). In obesity, enlarged adipocytes produce more pro-
inflammatory cytokines such as tumor necrosis factor alpha (TNF α) and interleukin 6 
(IL-6), and less anti-inflammatory factors such as adiponectin (3, 4). The regulation of 
ROS production and interactions among ROS, cytosolic Ca
2+
 signaling and mitochondrial 
uncoupling have been intensively investigated, and we have shown that calcitriol (1,25-
Dihydroxycholecalciferol) increases ROS production in both murine and human 
adipocytes by inhibiting adipocyte UCP2 expression, thereby increasing mitochondrial 
potential, and increasing cytosolic Ca
2+
 signaling (5).  Accordingly, since dietary calcium 
suppresses calcitriol, high calcium diets may correspondingly decrease adipose tissue 
ROS production and systemic oxidative stress.  Consistent with this concept, increasing 
dietary calcium decreases pro-inflammatory cytokine production and increases 
adiponectin production in mice (6, 7). 
These data provide a strong framework to explain a protective effect of dietary 
calcium against oxidative and inflammatory stress.  However, milk contains high 
concentrations of leucine and bioactive peptides that may further protect against 
oxidative and inflammatory stress.  Leucine has been shown to increase mitochondrial 
UCP2 expression and adiponectin production in differentiated 3T3-L1 adipocytes, and 
promote fatty acid oxidation in C2C12 muscle cells, while calcitriol exerted the opposite 
effects (8).  Furthermore, we have recently confirmed that dairy exerts a significantly 
greater effect on suppressing both local adipose tissue and systemic oxidative and 
inflammatory stress compared to supplemental calcium in mice (7).  Additionally, our 
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human data demonstrate that dairy-rich diets result in suppression of oxidative and 
inflammatory biomarkers (7).  In a recent follow-up randomized crossover study in 
overweight and obese subjects, we found that dairy supplementation suppressed both 
oxidative and inflammatory stress within seven days of initiation of supplementation, and 
that these effects increased in magnitude with increased duration of supplementation (9).  
Similar results were found in a 12-week study of metabolic syndrome patients (10). 
The adipose tissue cytokines we have demonstrated to be regulated by calcitriol 
and dairy components include several which affect vascular endothelial and smooth 
muscle cells (e.g. MCP-1, MIF, CD14, TNF-α, IL-6, IL-8, VEGF) and vascular 
infiltration by monocytes (11).  Accordingly, we tested the hypothesis that dairy food 
components, through modulation of adipokine production, can affect monocyte adhesion 
and subsequent migration across endothelial cells. 
 
3.3 Methods: 
3.3.1  Chemicals 
Calcitriol, leucine, 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate (DiI) and penicillin/streptomycin were obtained from Sigma (St. Louis, MO, 
USA).  Calcein AM and phosphate buffered saline (PBS) were obtained from Invitrogen 
(Carlsbad, CA, USA).  Fetal bovine serum for cell culture was obtained from Atlanta 
Biologicals (Lawrenceville, GA, USA). Hypoxanthine - Aminopterin – Thymidine 
(HAT) was obtained from ATCC (Manassas, VA, USA).  CD11b primary antibody (IgG) 
was purchased from AbCam (Cambridge, MA, USA).  CD54 primary antibody (IgG1) 
was purchased from Beckman Coulter (Brea, CA, USA).  AlexaFlour 488 goat anti-
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mouse secondary antibody, IgG and IgG1 specific, were purchased from Jackson 
ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). 
 
3.3.2  Cell Culture 
3T3-L1 preadipocytes were purchased from ATCC (Manassas, VA, USA) and 




 dish) and grown in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and antibiotics 
(adipocyte medium) at 37C in 5% CO2 in air.  Confluent preadipocytes were induced to 
differentiate with a standard differentiation medium consisting of DMEM-F10 (1:1, v/v) 
medium supplemented with 1% FBS, 1 M dexamethasone, 0.5 mM 
isobutylmethylxanthine, and antibiotics (1% penicillin/streptomycin).  Preadipocytes 
were maintained in this differentiation medium for 3 days and subsequently cultured in 
adipocyte medium (day 0).  Cultures were re-fed every 2 to 3 days to allow 90% cells to 
reach full differentiation before chemical treatment.  After 12-14 days, differentiated 
adipocytes were treated with vehicle (control), 0.5 mM leucine, 10 nM calcitriol, or both 
for 48 hours.  After treatment, the conditioned medium (CM) was collected, aliquoted 
and frozen at -80C until needed for subsequent assays.  For comparative purposes, all 
assays utilized CM (control vs. treatment group) derived from the same set of 3T3-L1 
cultures (ie. the same passage and treatment period). 
 EA hy.926 endothelial cells (12) were a gift from Dr. Ali Amirkhosravi (Florida 
Hospital, Center for Thrombosis Research, Orlando, FL), and were cultured in T-75 cm
2
 
flasks (Corning) with DMEM supplemented with 10% FBS, antibiotics (1% penicillin 
streptomycin), and HAT according to manufacturer’s instructions.  U937 monocyte cells 
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were obtained from ATCC (Manassas, VA, USA) and cultured in T-75 cm
2
 flasks with 
RPMI 1640 medium supplemented with 10% FBS and antibiotics (1% 
penicillin/streptomycin). 
 
3.3.3  Cell Preparation 
 EA hy.926 cells were cultured as described above until ~90% confluent.  Cells 
were then removed from the T-75 cm
2
 flask with trypsin (0.25%) / EDTA (0.1M), and 
centrifuged at 200 x g for 5 minutes.  The cells were resuspended with 3 mL of cell 
culture media and counted using an improved Neubauer cell counting chamber with 
trypan blue staining to assess viability.  The cells were seeded onto 40 mm glass 
coverslips at a final concentration of 2.5 x 10
5
 cells/mL and incubated at 37C, 5% CO2 
for 12-24 hours until ~90% confluent.  Cells were washed 3 times with 1X PBS and 
fluorescently labeled with Calcein AM (1 g/mL) for 30 minutes at 37C, 5% CO2.  
Afterwards, the coverslips were washed 3 times with 1X PBS to remove excess Calcein 
AM. 
U937 cells were centrifuged at 200 x g for 5 minutes.  The cells were resuspended 
in 3 mL of FBS free, phenol red free medium and counted as previously described.  
Viability of U937 cells was >90% for all assays.  U937 cells were adjusted to a final 
concentration of 1.0 x 10
6
 cells/mL.  The cells were fluorescently labeled with DiI at a 
final concentration of 4.16 g/mL for 20 minutes at 37C, 5% CO2.  After labeling, the 
cells were topped off with FBS free, phenol red free RPMI 1640 medium and centrifuged 
at 200 x g for 10 minutes.  The supernatant was removed and the labeled U937 cells were 
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resuspended with 3 mL of adipocyte CM (1.0 x 10
6
 cells/mL final concentration), or 3 
mL of clinical trial human plasma (diluted 1:1 in 1X PBS). 
 
3.3.4  U937 Cell Adhesion Assay 
This assay was modified from the principles previously described (13).  Briefly, a 
coverslip containing a monolayer of Calcein AM labeled EA hy.926 cells was assembled 
in an FCS2 microscope stage mounted perfusion system (Bioptechs Inc, Butler, PA) 
containing 0.5 mm gaskets.  FBS free, phenol red free RPMI 1640 cell culture media was 
perfused across the EA hy.926 monolayer at a flow rate of 0.5 mL/min (shear rate = 
132.9 s
-1
) for 10 minutes.  Afterwards, the pump was stopped and the affluent tubing was 
placed in a 12 x 75 mm tube containing the prepared U937 cells in adipocyte CM.  The 
pump was restarted and run for 5.5 minutes, which was the optimized time to allow fluid 
to flow through the entire system to the effluent end.  The pump was then stopped, and 
the effluent end of the tubing was placed back into the original 12 x 75 mm tube, 
allowing for a continuous, recycled perfusion.  The pump was then restarted and run for 1 
hr.  Afterwards, unbound U937 cells were washed off for 10 minutes with FBS-free, 
phenol red-free RPMI 1640 media.  For comparative purposes, a perfusion with the 
control CM was run every day prior to running a perfusion with a given treatment group 
CM.  This allowed for each treatment group perfusion (leucine, calcitriol, or both) to be 





3.3.5  Cell Migration Assay 
 This assay was modified from the principles previously described (13).  EA 
hy.926 cells were seeded onto 8 m pore size transwell inserts (Corning) at a 
concentration of 2.0 x 10
6
 / mL and incubated at 37C, 5% CO2 for 24 hours or until cells 
were confluent.  U937 cells were fluorescently labeled with DiI and resuspended in 
adipocyte CM as previously described.  2.0 x 10
5
 cells were added to the top of the 
transwell insert, and the adipocyte CM was placed in the bottom of the well to act as the 
chemoattractant.  The plate was incubated at 37C, 5% CO2 conditions for 18 hours and 
cell migration was assessed using a Perkin-Elmer Victor 3 fluorescent plate reader and 
confirmed by microscopy. 
 
3.3.6  Adhesion Molecule Expression by Flow Cytometry 
U937 cells adjusted to a concentration of 5.0 x 10
5
 cells/mL were centrifuged at 
200 x g for 5 minutes.  Cell pellets were resuspended in 1 mL of adipocyte CM and 
incubated at 37C, 5% CO2 for 1 hour.  After treatment, U937 cells were centrifuged at 
200 x g for 5 minutes and resuspended in 1 mL of  2% paraformaldehyde for 10 minutes.  
The tubes were topped off with 1 X PBS and centrifuged as previously described.  One 
microgram of mouse, anti-human CD11b monoclonal antibody was diluted in 1 mL of 1 
X PBS and used to resuspend the cell pellets.  The primary antibody was incubated at 
25C for 1 hr.  The cells were washed with 1 X PBS and centrifuged as previously 
described.  One microgram of goat, anti-mouse IgG secondary antibody conjugated to 
Alexaflour 488 was diluted in 1 mL of 1 X PBS and allowed to incubate with the cells for 
30 minutes at 25C.  Cells were washed, centrifuged and resuspended in 1 X PBS.  Flow 
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cytometry was performed on an Accuri C6 Cytometer (Ann Arbor, MI).  Twenty 
thousand events were collected and a marker gate was set on the isotypic control.  The 
same gate was applied to the CD11b stained samples generating a percent of cells that are 
positive for CD11b  SEM. 
EA hy.926 cells were cultured as previously described.  Cells (1.5 x 10
5
) were 
seeded in each well of a 6 well plate and grown at 37C, 5% CO2 for 12-24 hours until 
~90% confluent.  EA hy.926 cells were washed with PBS and incubated with 2 mL of the 
various adipocyte CM for 8 hours at 37C, 5% CO2.  After incubation, the cells were 
washed 3 times with PBS and removed from the wells with trypsin (0.25%) / EDTA 
(0.1M).  Cells were centrifuged at 300 x g for 5 minutes and resuspended in 2% 
paraformaldehyde for 10 minutes for fixation.  The tubes were topped off with PBS and 
centrifuged as previously described.  Cell pellets were resuspended in 100 L of PBS and 
incubated with one microgram of mouse, anti-human CD54 monoclonal antibody for 1 
hr. at 25C.  Cells were washed with PBS and centrifuged as previously described.  Cell 
pellets were resuspended in 100 L of PBS and incubated with one microgram of goat, 
anti-mouse Alexa 488 (IgG1) secondary antibody for 45 minutes at 25C.  Cells were 
washed with PBS and centrifuged as previously described.  Pellets were resuspended in 
300 L of PBS and analyzed by flow cytometry as described above.  
 
3.3.7  Microscopy and Image Analysis  
 Microscopy was performed on a Nikon Eclipse Ti-E Epi-fluorescence microscope 
equipped with an automated stage and a 20 X objective.  A 3 x 3 large image scan was 
taken in each of 5 random fields by multi-channel capture (channel 1: excitation/emission 
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= 488/517 nm, channel 2: ex/em = 550/567 nm).  Image analysis was performed using 
Nikon Elements 3.1 software.  Binary thresholding was individually applied to both cell 
types to exclude non-specific staining, generating a percent area occupied by 
fluorescence, which has been shown to be a direct correlation to the cell count (14).  
Results are presented as the ratio of percent area occupied by fluorescence (U937 : EA 
hy.926). 
 
3.3.8  Clinical Samples 
 Plasma samples from a recently completed clinical trial (10) were utilized to 
evaluate the effects of feeding a dairy-rich diet on monocyte adhesion to endothelial cells.  
These studies were conducted as described above, with plasma (diluted 1:1 in 1 X PBS) 
substituted for the adipocyte CM.  Briefly, 40 overweight and obese subjects participated 
in a 12-week randomized clinical trial of low (<0.5 serving/day) vs. high (>3.5 
servings/day) intakes of dairy foods.  Blood was drawn at baseline, day 7 and day 84 for 
assessment of inflammatory and oxidative stress markers, and archival samples were used 
for this study.  This study was approved from an ethical standpoint by the Institutional 
Review Board at the University of Tennessee-Knoxville; standardized informed consent 
was obtained from all subjects, and the research was conducted in accordance with the 
ethical standards outlined in the Helsinki Declaration.  Details of this clinical trial are 





3.3.9  Statistical Analysis 
Data from each day was normalized to control by dividing each individual 
treatment value by the mean control value from that days experiment.  Normalized data 
were analyzed via analysis of variance after confirming equality of variance among 
groups and normality of distribution, and significantly different group means were 
separated by Fisher’s LSD.   
 
3.4 Results: 
 Calcitriol conditioned medium (CM) stimulated a 347% increase in monocyte 
adhesion when perfused across a monolayer of EA hy.926 cells compared to the control 
CM (representative images shown in Fig 3-1A vs. B; p <0.0001).  In contrast, leucine 
CM elicited a 61% reduction in monocyte adhesion to the endothelial cell monolayer 
compared to the control CM (Fig 3-1A vs. C; p =0.0485).  Interestingly, when the two 
treatments were combined, leucine was able to completely abolish the effects of 
calcitriol, resulting in an 81% reduction in monocyte adherence compared to the control 
(Fig 3-1A vs. D; p=0.0096).  These quantitative comparisons are summarized in Fig 3-
1E. 
 Parallel experiments were performed to assess the effects of the CM on monocyte 
CD11b expression, as CD11b is directly involved in adhesion to and migration across the 
endothelial layer.  When monocytes were incubated for 1 hr with calcitriol CM, the 
percentage CD11b-positive cells increased from 3.9%  0.12 (control) to 4.3%  0.06 
(Fig 3-2A; p=0.0196).  Conversely, monocytes treated with leucine CM resulted in a 
decrease in CD11b-positive cells (2.7%  0.06; Fig 3-2A; p=0.0069).  When the leucine 
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and calcitriol treatments were combined, the percent of cells positive for CD11b was 
reduced to 2.6%  0.13, comparable to the leucine treatment in the absence of calcitriol 
(Fig 3-2A; p=0.0029).  These results show an identical trend to the monocyte adhesion 
data, suggesting a positive role for leucine in modulating adhesion molecule expression 
via adipocyte derived compound(s).  
  An additional adhesion molecule required for diapedesis of monocytes across the 
vascular endothelial layer, ICAM-1 or CD54, which is expressed by activated endothelial 
cells, was also measured by flow cytometry.  After 8 hrs of treatment with the control 
CM, the percent of EA hy.926 cells positive for CD54 was 2.38%  0.29 (Fig 3-2B).  The 
calcitriol CM treatment resulted in a significant increase to 4.74%  0.69 percent positive 
cells compared to control (Fig 3-2B; p=0.0006).  Similar to the CD11b expression data, 
when the two treatments were combined, leucine was able to significantly overcome the 
effects of calcitriol resulting in 1.58  0.17% of EA hy.926 cells positive for CD54 (Fig 
3-2B; p=0.0147 vs. calcitriol).  This CD54 expression data shows a similar trend to the 
CD11b expression data, suggesting that the adipocyte derived factors generated by 
treatment with leucine can affect adhesion molecule expression on both monocytes and 
endothelial cells.   
 The effect of the various CM on diapedesis was also performed, as monocyte 
migration across the endothelial layer is directly involved in the inflammatory response.  
Although the observed trend was similar to the adhesion data, these differences were not 
significant (Fig 3-3).  
Because dairy foods are rich in both leucine and calcium, resulting in suppression 
of calcitriol and elevated postprandial leucine, an ex vivo approach was used to assess the 
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effects of low vs. high dairy diets on monocyte adhesion to endothelial cells.  When 
human plasma samples from obese subjects on low or high dairy diets were used in place 
of the adipocyte CM, plasma from the high dairy group significantly reduced U937 
adhesion by 68% in perfusions with plasma samples taken after the patients were on a 
high dairy diet for 7 days (Fig 3-4E; p =0.0031), and this reduction was sustained (57%) 
following 84 days on the high dairy diet (Fig 3-4F; p =0.0129 vs. baseline).  In contrast, 
plasma samples from patients receiving a low dairy diet exerted the opposite effect with 
an 80% increase at day 7 (Fig 3-4B; p =0.0006) and a further 116% increase at day 84 




Data from this study demonstrate that treatment of adipocytes with calcitriol 
significantly increases pro-inflammatory events, including monocyte CD11b expression, 
endothelial ICAM-1 expression, and monocyte adhesion to an endothelial cell monolayer, 
while leucine exerts the opposite effect.  Similarly, Zehnder et. al. reported that calcitriol 
treatment of endothelial cells significantly increased U937 adhesion (15).  Moreover, 
calcitriol induces monocyte-macrophage differentiation (16, 17), further contributing to a 
pro-inflammatory state.  Notably, the effects of leucine were sufficiently robust to fully 
reverse these effects of calcitriol when the two treatments were combined. 
We have previously demonstrated that dietary calcium-induced suppression of 
calcitriol reduces oxidative and inflammatory biomarkers in both mice and humans (7, 9, 
10).  However, calcium from dairy exerts greater effects than supplemental calcium, 
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suggesting the presence of an additional bioactive component(s) (7, 18).  Dairy products 
are rich in the branched-chain amino acid leucine; our previous data (8, 19) coupled with 
the data from the present study suggest that leucine is the primary contributor to this 
additional bioactivity.  Leucine increases both mitochondrial UCP2 expression and 
adiponectin production in differentiated 3T3-L1 adipocytes while calcitriol exerts the 
opposite effects (8).  Increasing mitochondrial uncoupling status in adipocytes provides a 
potential mechanism to alleviate the increased oxidative stress present during an obese 
state.  Since high levels of ROS can lead to an increase in pro-inflammatory cytokine 
production in adipocytes (6, 7), it is possible that leucine indirectly reduces pro-
inflammatory cytokines by attenuating ROS production and oxidative stress.  
Adiponectin, an adipocyte-derived cytokine that increases expression upon leucine 
treatment, has anti-inflammatory effects by suppressing TNF- induced adhesion 
molecule expression through inhibition of IB--NF-B activation via a cAMP-
dependent pathway in human aortic endothelial cells (20).  In support of this concept, 
Macotela et al. recently demonstrated that a two-fold increase in dietary leucine 
prevented the macrophage infiltration of adipose tissue induced by dietary fat in mice and 
reduced inflammatory markers, including TNF-α, by 40-45% (21).  Moreover, our recent 
data demonstrates that leucine stimulates SIRT1 activity in skeletal muscle and 
adipocytes, resulting in stimulation of PGC1- expression and mitochondrial biogenesis 
and decreases in ROS production and NF-B activation (22).  Accordingly, using dairy to 
deliver both leucine and calcium may reduce obesity-induced oxidative and inflammatory 
stress via multiple mechanisms. 
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It is possible that dairy modulation of adipokine production could generate a 
functional effect on cell-to-cell interactions that occur during an obesity-induced 
inflammatory response, in vivo.  Therefore, we have applied this concept in a novel ex 
vivo assay to assess monocyte – endothelial cell adhesion in the presence of human 
plasma from obese clinical trial participants consuming either an adequate dairy (>3.5 
servings/d) or low dairy (<0.5 servings/d) diet for 12 weeks.  Our results show adequate 
dairy consumption results in significant, sustained decreases in monocyte – endothelial 
cell adhesion, whereas low dairy consumption had the opposite effect in this model 
system.  These findings are further supported by our in vivo data from the clinical trial 
demonstrating significant decreases in the inflammatory stress biomarkers TNF-, MCP-
1, IL-6, and C-reactive protein in those individuals consuming adequate dairy over the 
12-week period (9, 10).  Furthermore, a recent study from Thomas et al. showed 
significant reductions of white adipose tissue pro-inflammatory cytokines in diet induced 
obese mice fed a high-Ca
2+
 plus non-fat dairy diet when compared to high-Ca
2+
 alone, 
although these differences were not observed after controlling for body weight (18).  In 
contrast, two other studies showed little or no effect of dairy foods on inflammatory 
biomarkers (23, 24).  However, in both cases the levels of calcium and dairy consumption 
prior to intervention were close to adequate, leaving little opportunity for dairy to exert 
an effect.  A more recent study from Van Loan et al. showed no effect of dairy food 
consumption on inflammatory biomarkers (25); the reason for the discrepancy is not 
clear. 
Obesity is associated with sub-clinical chronic inflammation (26) that plays an 
important role in the initiation and progression of cardiovascular diseases such as 
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atherosclerosis, which is characterized by a thickening of the arterial wall with fatty 
deposits (plaque).  An additional hallmark of atherosclerotic lesion development is a 
localized increase in monocyte adhesion to the endothelium and infiltration to the intima 
where they can differentiate into macrophages.  The adipose tissue cytokines we have 
previously demonstrated to be regulated by calcitriol and dairy components include 
several which affect vascular endothelial and smooth muscle cells (e.g. MCP-1, MIF, 
ICAM-1, TNF-, IL-6, IL-8, VEGF) and vascular infiltration by monocytes (MAC-1, 
MCP-1, ICAM-1, TNF-) (11).  Therefore, modulation of adipocyte-derived 
inflammatory cytokines via dairy consumption could provide a potential mechanism to 
reduce the initial stages of atherosclerotic lesion development independently of its 
proposed anti-obesity and anti-hypertensive properties. 
Strengths of this study include targeting the cumulative effects of calcitriol and 
leucine treatment of adipocytes through the collection of adipocyte-derived factors 
present in conditioned media.  Since adipose tissue is capable of producing a variety of 
co-factors that could affect monocyte – endothelial cell interactions, it is important to 
account for the balance between the components rather than solely utilizing a specific 
compound.  Additionally, we applied a novel, ex vivo style approach to confirm our in 
vitro model of assessing monocyte – endothelial cell adhesion by using human plasma 
samples from patients consuming adequate or low dairy diets.  Similar to the in vitro 
assessment, this approach targets the cumulative effects of dairy consumption on a 
systemic level rather than solely its effects on adipose tissue.  However, our model of 
assessing cell adhesion has some limitations.  In this study design, we did not assess the 
mechanisms responsible for the changes in cell adhesion, and we are unable to yet 
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identify how leucine alters adipokine expression.  Similarly, the ex vivo approach also 
lacks the mechanistic detail, and although it does not provide direct evidence, it does 
model what would occur in a clinical setting. 
In summary, data from this study confirms our previous work and provides 
additional evidence suggesting that dairy components have the ability to modulate 
adipocyte inflammatory cytokine production that attenuates monocyte – endothelial cell 
adhesion, in vitro.  Furthermore, utilization of human plasma from obese patients who 
increase their dairy intake significantly reduces monocyte – endothelial cell adhesion 
using a novel, ex vivo approach, suggesting a possible in vivo mechanism to reduce 
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Figure 3-1:  Effects of adipocyte CM on U937 – EA hy.926 cell adhesion under flow 
conditions.  DiI labeled U937 cells (red) were resuspended in the various CM and 
perfused across a monolayer of Calcein AM labeled EA hy.926 cells (green) for 1 hr. 
Adhesion was quantified by microscopy and image analysis.  Representative images of 
control (A), calcitriol (B), leucine (C) or the two treatments combined (D) are shown. 
Results are presented as the normalized percent area occupied by fluorescence  SEM 
(E).  Differing letters above the bars denote significant differences between groups (a = 





















Figure 3-2:  Effects of adipocyte CM on U937 – CD11b expression (A) and EA 
hy.926 – ICAM-1 expression (B).  Differentiated 3T3-L1 adipocytes were treated for 48 
hrs with calcitriol (10 nM), leucine (0.5 mM), or the two combined and CM was 
collected.  U937 or EA hy.926 cells were incubated with the adipocyte CM for 1 hr and 8 
hrs, respectively.  Cells were labeled with specific mAbs and analyzed by flow 
cytometry.  Results are presented as percent positive cells ± SEM.  Differing letters above 
the bars denote significant differences between groups (a = different from control; b = 







Figure 3-3:  Effects of adipocyte CM on transmigration of U937 cells across an EA 
hy.926 cell monolayer.  DiI labeled U937 cells were resuspended in the previously 
described adipocyte CM and added to transwell inserts containing a monolayer of EA 
hy.926 cells.  After 18 hr incubation, U937 migration was assessed using a fluorescent 








Figure 3-4:  Effects of plasma from humans consuming low and high dairy diets on 
monocyte – endothelial cell adhesion ex vivo.  Similar to the in vitro assay, plasma 
samples taken at baseline, day 7 and day 84 were prepared as described.  DiI labeled 
U937 cells were resuspended in the prepared plasma and perfused across a monolayer of 
Calcein AM labeled EA hy.926 cells for 1 hr. Adhesion was quantified by microscopy 
and image analysis.  Representative images of low dairy baseline (A), day 7 (B), day 84 
(C), high dairy baseline (D), day 7 (E), and day 84 (F) are shown. Results are presented 
as the percent area occupied by fluorescence normalized to control  SEM (G).  Differing 
letters above the bars denote significant differences between groups (a = different from 




































Leucine Induced Adiponectin Expression on Adipocyte Derived 












4.1  Abstract: 
 We previously demonstrated that calcitriol and leucine modulate adipocyte 
cytokine production.  Specifically, calcitriol increases the production of pro-
inflammatory cytokines, such as TNF-, MCP-1 and IL-6, and decreases the production 
of anti-inflammatory cytokines (adiponectin) while leucine exerts the opposite effect.  
The modulation of inflammatory cytokine production also had corresponding effects on 
monocyte-vascular endothelial cell adhesion in vitro and ex vivo and on monocyte CD11b 
and endothelial cell ICAM-1 expression.  Recent evidence suggests that adipocyte 
derived microparticles (ADMs) may serve as a messenger system between adipose tissue 
and peripheral blood.  Therefore, we tested the hypothesis that ADMs isolated from 
leucine treatment of 3T3-L1 adipocytes will reduce monocyte CD11b expression in fresh 
human blood.  3T3-L1 cultures were treated with vehicle (control) or 0.5 mM leucine for 
48 hrs and the conditioned media (CM) was collected.  ADMs were isolated by 
ultracentrifugation and samples of CM, supernatant fraction, and ADM fraction were 
incubated with fresh whole blood for 2 and 18 hrs.  Monocyte CD11b expression was 
assessed using flow cytometry.  After 2 hrs, monocyte CD11b+, expressed as the percent 
of monocytes positive for CD11b, decreased from 68.6  3.4% (control) to 47.7  7.6% 
in the presence of leucine CM, and the leucine ADMs recapitulated this effect.  Similarly, 
leucine ADMs reduced monocyte CD11b+ from 72.1  4.0% (control) to 48.4  2.7% (p 
<0.05) following 18-hr incubation.  These effects were reversed when cells were 
transfected with adiponectin siRNA.  These data suggest that leucine treatment of 
adipocytes reduces CD11b expression on fresh human monocytes and that adiponectin 
present on ADMs mediate these effects.   
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4.2  Introduction: 
 Microvesicles are membrane vesicles that range from 50 nm to 3 m in diameter, 
and are released from the origin cell type into the microenvironment under normal 
physiological conditions (1-3).  The term “microvesicles” is used here as a collective 
term referring to both membrane budding vesicles and exosomes.  The properties of 
cellular vesicles have been reviewed extensively (3-11).  Briefly, these vesicles have been 
shown to carry diverse membrane and cytosolic proteins as well as messenger and 
microRNAs (miRNAs) (3-5).  These factors can affect the physiology of their target cells 
by transferring these proteins and genetic material.  For example, they can induce 
intracellular signaling following binding to receptors, or they can confer new properties 
after the acquisition of new receptors, enzymes, or genetic material by fusion or 
endocytosis (3-5).  Furthermore, microvesicles can participate in physiological processes 
including hemostasis and thrombosis, inflammation, immune interactions, and 
angiogenesis (5, 12).  Studies have shown elevated levels of microvesicles in blood 
circulation in various disorders, including atherosclerosis and coronary heart disease, pre-
eclampsia, hematological and inflammatory diseases, diabetes, and cancer (5).   
Recent studies have confirmed that adipocytes also release microvesicles into 
their microenvironment (6, 8, 13-19).  Aoki et al. characterized the protein composition 
of adipocyte derived microvesicles (ADMs) secreted from the adipocyte cell line 3T3-L1 
(13).  In another study, microvesicles isolated from the adipose tissue of obese mice were 
injected into wild type showed that the ADMs are taken up by monocytes, which 
differentiate into macrophages and secrete increased levels of TNF- and IL-6 (14).  
Sano et al. isolated ADMs from differentiated 3T3-L1 cell culture supernatants and 
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demonstrated that exosomes isolated from cells cultured under hypoxic conditions are 
abundant in enzymes that promote lipogenesis, such as acetyl-CoA carboxylase, glucose-
6-phosphate dehydrogenase, fatty acid synthase, and these ADMs promoted lipid 
accumulation in recipient 3T3-L1 adipocytes (19).  Studies by Muller et al. provided 
evidence that stimulus-induced lipid synthesis between differently sized adipocytes is 
controlled by the release of ADM-associated CD73 from large cells and its subsequent 
translocation to lipid droplets of small cells (8, 16, 17).  This information transfer via 
ADMs harboring the glycosylphosphatidylinositol (GPI) anchored proteins may shift the 
burden of TAG storage from large to small adipocytes (8, 17).  These studies suggest that 
adipocytes produce microvesicles that may play a role in communication between 
adipocytes and macrophages, and could also serve as communication vectors between 
adipose tissue and systemic circulation. 
Adiponectin, a 247-amino acid protein that is one of the most abundant 
adipokines secreted by adipocytes, with circulating plasma levels ranging from 2-20 
g/mL in humans with a half-life of 2.5-6 hours (20).  Adiponectin has been shown to 
activate AMPK and sirtuin signaling pathways, which can directly increase insulin 
sensitivity through phosphorylation of peroxisome proliferator-activated receptor  co-
activator 1 alpha (PGC-1), a transcription co-activator that plays a critical role in 
mediating mitochondrial biogenesis and oxidative phosphorylation (21).  In the 
endothelial cell, adiponectin inhibits the production of inflammatory cytokines and 
adhesion molecules such as intracellular adhesion molecule 1 (ICAM-1), vascular cell 
adhesion molecule (VCAM) and E-selectin (22).  Leucine, a branched-chain amino acid 
abundant in dairy products, can increase adiponectin secretion in 3T3-L1 adipocytes 
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compared to control (23).  Furthermore, conditioned media collected from differentiated 
3T3-L1 cells after a 48 hr leucine treatment (0.5 mM) decreased CD11b expression in 
U937 cells (unpublished data).   
Adiponectin is one of the proteins carried by ADMs, and the HMW form is the 
most abundant form present in the exosomes (13, 18).  Most recently, Phoonsawat et al. 
has isolated ADMs carrying HMW adiponectin from the plasma of mice (18).  Since 
ADMs carrying adiponectin can enter systemic circulation, its possible that they can also 
exhibit anti-inflammatory effects, such as decreasing monocyte CD11b adhesion 
molecule expression.  Therefore, the purpose of this study is to determine if ADMs 
carrying adiponectin isolated from 3T3-L1 conditioned media mediate the effects 
observed with leucine treatment. 
 
4.3  Materials and Methods: 
4.3.1  Chemicals:  
Leucine, and penicillin/streptomycin were obtained from Sigma (St. Louis, MO, 
USA).  Phosphate buffered saline (PBS) was obtained from Invitrogen (Carlsbad, CA, 
USA).  Fetal bovine serum for cell culture was obtained from Atlanta Biologicals 
(Lawrenceville, GA, USA).  CD11b primary antibody (IgG2b) was purchased from 
AbCam (Cambridge, MA, USA).  CD14 primary antibody (IgG1) was purchased from R 
and D Systems (Minneapolis, MN, USA).  AlexaFlour 488 goat anti-mouse (IgG1 
specific) and AlexaFlour 647 goat anti-rat (IgG2b specific) secondary antibodies were 
purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA, USA). 
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4.3.2  Cell Culture 
3T3-L1 preadipocytes were purchased from ATCC (Manassas, VA, USA) and 




 dish) and grown in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and antibiotics 
(adipocyte medium) at 37C in 5% CO2 in air.  Confluent preadipocytes were induced to 
differentiate (day 0) with a standard differentiation medium consisting of DMEM-F10 
(1:1, v/v) medium supplemented with 1% FBS, 1 M dexamethasone, 0.5 mM 
isobutylmethylxanthine, and antibiotics (1% penicillin/streptomycin).  Preadipocytes 
were maintained in this differentiation medium for 3 days and subsequently cultured in 
adipocyte medium.  Cultures were re-fed every 2 to 3 days to allow 90% cells to reach 
full differentiation before chemical treatment.  After 7 days, differentiated adipocytes 
were treated with vehicle (control) or 0.5 mM leucine for 48 hours.  After treatment, the 
conditioned medium (CM) was collected, aliquoted and frozen at -80C until needed for 
subsequent assays.  For comparative purposes, all assays utilized CM (control vs. 
treatment group) derived from the same set of 3T3-L1 cultures (ie. the same passage and 
treatment period). 
 
4.3.3  siRNA Knockdown of Adiponectin: 
 3T3-L1 adipocytes were cultured and differentiated as described above.  On day 6 
of differentiation, 3T3-L1s were removed from the T-75 cm
2
 flask using trypsin/EDTA 
0.25% and 0.5 g/mL type I collagenase (to prevent clumping of cells).  Cells were 
centrifuged at 400 x g for 5 min and resuspended in 24 mL of media (10% FBS, 1% 
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pen/strep).  One mL was placed into each well of a 24 well plate and allowed to re-adhere 
overnight.   
Small interfering RNA for adiponectin and scrambled RNA (negative control) 
were obtained from Dharmacon, Inc (ThermoScientific; Waltham, MA, USA). A 5x 
siRNA solution was made according to the manufacture’s instructions and diluted to 1x 
for use.  The knockdown was optimized so that >60% reduction in adiponectin RNA 
expression was achieved.  Re-seeded 3T3-L1s were treated with siAdipoQ for 24 and 48 
hrs at a final concentration of 100, 200, and 300 nM.  After treatment, the media was 
changed to complete media and left for 48 hrs to confirm the duration of the knockdown.  
Optimized conditions were determined to be a 24 hr treatment with 200 nM siAdipoQ 
followed by 48 hrs of control (no treatment) or 0.5 mM leucine treatment.  
 
4.3.4  Total RNA Isolation: 
RNA isolation was performed per the manufacturer’s instructions using a total 
cellular RNA isolation kit (Ambion – Life Technologies; Grand Island, NY, USA).  The 
concentration and purity of the isolated RNA was then measured using a NanoDrop 
(A280/A260 between 1.9 and 2.1). 
 
4.3.5  RT-PCR: 
Adipocyte 18s and adiponectin were quantitatively measured using an ABI 7300 
Real-Time PCR System (Applied Biosystems, Branchburg, NJ) with a TaqMan 1000 
Core Reagent Kit (Applied Biosystems, Branchburg, NJ).  Primer and probe sets were 
purchased from Applied Biosystems TaqMan Assays-on-Demand and utilized according 
 103 
to manufacturer instructions.  A standard curve was generated using pooled total RNA 
from each sample and were serial-diluted (50-1.5625 ng).  Reactions of quantitative RT-
PCR for standards and unknown samples were performed per ABI 7300 Real-Time PCR 
System and TaqMan Real-Time PCR Core Kit instructions.  The mRNA quantitation for 
each sample was normalized using the corresponding 18s. 
 
4.3.6  Preparation of ADMs from Conditioned Media: 
The stored 3T3-L1 CM was thawed using a 37C water bath for 15 min.  The 
tubes were centrifuged at 1500 x g for 15 minutes to remove cell debris (24) and the 
supernatant was transferred to a 5 mL ultracentrifuge tube (Beckman Coulter; Pasadena, 
CA, USA).  The CM samples were subjected to high-speed centrifugation for 1.25 hrs at 
115,000 x g and 4C to remove the ADM fraction from the CM.  The supernatant was 
carefully removed and placed in a separate tube.  The ADM pellet was re-suspended in 
500 L of antibiotic/serum-free DMEM.   
 
4.3.7  Phlebotomy: 
Blood draws were approved from an ethical standpoint by the Institutional 
Review Board at the University of Tennessee (IRB #8961 B).  Subjects interested in 
donating blood were required to meet standard inclusion criteria guidelines that were out 
lined in the screening form.   Blood was drawn using a 19-guage butterfly needle 
equipped with a vaccutainer connection and 10-30 mL of blood was collected each time 
into sodium heparin vaccutainer tubes (BD Biosciences; San Jose, CA, USA).  Blood was 
immediately used for all assays described below. 
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4.3.8  Whole Blood Monocyte CD11b Expression: 
Five hundred L of whole blood was added to 200 L of the prepared ADMs, 
supernatant, or whole conditioned media in a 2 mL eppendorf tube.  Samples were gently 
mixed with a pipette and incubated at 37C.  After both 2 hrs and 18 hrs, a 100 L 
blood/ADM sample was added to 65L of 10% paraformaldehyde (4% final 
concentration) and incubated at room temperature for 10 minutes to fix the cells.  The 
tubes were topped off with 1X PBS and centrifuged for 10 min at 300 x g.  The 
supernatant was removed and the pellet was gently resuspended in 100 L of 1X PBS.  
Then, 0.5 g of each primary antibody (AbCam; Cambridge, England, UK) specific for 
human CD11b (IgG2b) and CD14 (IgG1) were added to each tube and incubated for 1 hr 
at room temperature.  The same concentration of matching isotype was added to a 
separate tube and used as a negative control.  After primary antibody incubation, the 
tubes were topped off with 1X PBS and centrifuged for 10 min at 300 x g.  The 
supernatant was removed and the pellet was gently resuspended in 100 L of 1X PBS.  
Then, 0.5 g of each secondary antibody (IgG1-DyLite 488 and IgG2b-APC) were added 
to each tube and incubated at room temperature for 45 minutes.  After secondary 
antibody incubation, the tubes were topped off and centrifuged as before.  Cell pellets 
were resuspended in 1 mL of red blood cell lyse solution (BD Biosciences; Franklin 
Lakes, NJ, USA) and incubated for 10 minutes.  After incubation with the lyse solution, 
tubes were centrifuged as previously described and resuspended in 300 L of 1X PBS 




4.3.9  Flow Cytometry of Whole Blood: 
 The dual color staining method was designed to allow for the identification of 
monocytes (CD14+) also expressing the adhesion molecule CD11b. Therefore, CD14 
was tagged with a green fluorescent marker (DyLite 488) and CD11b was tagged with a 
red fluorescent marker (APC) as previously described (25).  Samples were analyzed on 
an Accuri C6 flow cytometer (BD Biosciences).  Initially, 10,000 events were collected 
to generate a typical whole blood profile on the forward scatter (FSC) vs. side scatter 
(SSC) plot.  Then, a gate was placed around the monocyte population (Gate 1).  Gate 1 
was then applied to two separate histogram plots of green fluorescence (CD14 
expression; H1 plot) and red fluorescence (CD11b expression; H2 plot) where isotypic 
control gates were set to 1% positive.  Therefore, anything above the fluorescence level 
of the isotypic control for both green and red fluorescence was considered positive for 
CD14 and CD11b, respectively.  A test sample was allowed to run until 10,000 events in 
gate 1 were collected.  Those events were then applied to the H1 plot and the positive 
events were further applied to the H2 plot.  Then, the percent of CD14+ cells also 
positive for CD11b were recorded.  Each treatment condition was run in triplicate and 
repeated 3 times.  Results are presented as mean percent positive  standard error mean 
from the 3 independent experiments. 
 
4.3.10  Statistical Analysis: 
Unless otherwise specified, data is presented as mean  standard error mean 
(SEM).  Data was analyzed via one-way analysis of variance after confirming equality of 
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variance among groups and normality of distribution.  Significantly different means (p< 
0.05) were separated by Fisher’s LSD using GraphPad Prism (GraphPad Software, Inc.).   
 
4.4  Results: 
 Compared to control, leucine CM incubated with whole blood for 2 hrs. reduced 
monocyte CD11b expression from 71.6  2.9% to 52.7  5.8% (Fig 4-1A; p<0.03), and 
this effect was sustained throughout the 18 hr incubation (Fig 4-1B; p<0.004).  The 
isolated ADM fraction from the leucine CM mimicked the effects of the whole CM at 
both the 2 and 18 hr time points, reducing monocyte CD11b expression from 73.4  3.2% 
to 50.6  7% (2 hr; p<0.008) and from 75.6  3.4% to 49.6  1.9% (18 hr; p<0.0001), 
respectively (Fig 4-1A and B).  The supernatant fraction from the CM exhibited no 
significant effects at either time point (Fig 4-1A and B), suggesting the ADM fraction of 
the CM contains an active component capable of reducing monocyte CD11b expression. 
 We have previously shown that treating 3T3-L1 adipocytes with leucine (0.5 mM) 
increases adiponectin production (23), and others have shown that adiponectin is present 
on ADMs (13, 14, 18).  Therefore, we knocked down adiponectin production using 
siRNA by ~60% compared to untransfected cells and cells treated with non-specific 
scrambled RNA (Fig 4-2A; p<0.02).  After optimizing our knockdown efficiency, we 
applied our adipocyte treatments to determine transcriptional levels of adiponectin.  In 
untransfected 3T3-L1 adipocytes, leucine treatment significantly increased adiponectin 
mRNA levels by 35% compared to control (Fig 4-2B; p<0.02).  However, when the cells 
were treated with siAdipoQ, it significantly reduced adiponectin mRNA levels compared 
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to untransfected cells (Fig 4-2B; p<0.02) within each treatment group, but there was no 
difference between leucine and control treatment groups (Fig 4-2B).   
 The same siAdipoQ transfection and treatments were used to generate adipocyte 
CM for the control (no treatment) and 0.5 mM leucine groups.  The CMs were further 
separated using ultracentrifugation to isolate ADMs and the remaining supernatant.  The 
whole CM, supernatant, and isolated ADMs were applied to samples of whole blood and 
incubated for 2 and 18 hours.  Consistent with our previous data, untransfected leucine 
CM decreased monocyte CD11b expression from 24.2  1.4% to 20.4  1.2% (Fig 4-3A; 
p<0.04) at the 2 hr time point and from 73.9  1.1% to 68.6  1.3% at 18 hrs (Fig 4-4A; 
p<0.001).  Adiponectin siRNA reversed this effect, resulting in a significant increase 
compared to the leucine untransfected group at both time points (Fig 4-3A and 4-4A; 
p<0.004).  The supernatant fraction had no significant effects between treatment groups 
or between transfection groups at the 2 hr time point (Fig 4-3B).  The ADM fraction 
showed the same trend as the whole CM with leucine significantly reducing monocyte 
CD11b expression from 24.2  1.8% to 9.1  0.3% after a 2 hr incubation (Fig 4-3C; 
p<0.0001) and from 68.7  1.8% to 64.1  0.7% after 18 hrs. (Fig 4-4C; p<0.003).  
Again, adiponectin siRNA reversed this effect, resulting in a significant increase 
compared to the leucine untransfected group at both time points (Fig 4-3C and Fig 4-4C; 
p<0.0001).  Collectively, these results suggest that leucine treatment of adipocytes 
decreases monocyte CD11b expression, and adiponectin present on ADMs are directly 




4.5  Discussion: 
 Data from this study demonstrate that treating adipocytes with leucine reduce 
CD11b expression on peripheral blood monocytes and adipocyte derived microvesicles 
mediate this process.  We have shown similar effects with CD11b expression in U937 
cells and ICAM-1 expression on endothelial cells treated with control and leucine CM 
(unpublished data).  Isolating the ADM fraction exhibited similar effects on monocyte 
CD11b expression compared to the whole CM, while the supernatant fraction did not, 
suggesting the ADM fraction mediates this process.  Microvesicles appear to be involved 
in intercellular cross-talk in both normal and pathological conditions (26, 27).  Adipocyte 
derived microvesicles released from obese mice (obADMs) are preferentially taken up by 
peripheral blood monocytes, and stimulate monocyte to macrophage differentiation (14).  
Furthermore, when the obADMs were injected into wild-type mice it induced an insulin-
resistant phenotype (14), suggesting ADMs mediate communication from adipose tissue 
to cells in systemic circulation.  Therefore, its possible that leucine supplementation 
through dairy products can alter the ADM profile that acts on circulating monocytes, 
leading to decreased adhesion to endothelial cells.  This would decrease 
monocyte/macrophage infiltration into adipose tissue to subsequently reduce obesity 
associated inflammatory stress.   
 Our previous in vitro studies (23) and studies in mice and humans demonstrate 
that leucine increases adiponectin secretion (28, 29) through a Sirtuin 1 (SIRT1)/AMPK 
mediated mechanism.  In the current study, we demonstrate leucine treatment of 
adipocytes also increases adiponectin mRNA levels.  Therefore, adiponectin is a probable 
candidate mediating the reduction in monocyte CD11b expression.  Indeed, after 
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knocking down adiponectin expression, the collected leucine CM did not reduce 
monocyte CD11b expression compared to control (Fig 4-3).  These effects were also 
observed in the isolated ADM fraction, but not the supernatant fraction, suggesting 
adiponectin is present on the ADM fraction.  Similarly, multiple other studies have also 
demonstrated adiponectin associated ADMs, specifically the high-molecular weight form 
(14, 18, 19).  The three forms of adiponectin have been shown to possess different 
biological activities, and the HMW form is considered the major active form in 
circulation, providing the insulin-sensitizing and cardiovascular protective effects 
observed with adiponectin (30, 31).   
 Adiponectin exerts its signaling actions through two receptors, adiponectin 
receptor 1 and 2 (AdipoR1 and AdipoR2) (32).  One pathway that adiponectin activates is 
5’-adenosine monophosphate kinase (AMPK) activity, which stimulates fatty-acid 
oxidation, increases PPAR expression, and increases glucose uptake while 
simultaneously inhibiting glycolysis, lipogensis and gluconeogenesis (33).  Adiponectin 
can also exert anti-atherosclerotic effects through modulation of multiple points of the 
inflammatory process (34).  For example, adiponectin prevented atherosclerosis by 
increasing cholesterol efflux from macrophages (35).  Furthermore, in human monocyte-
derived macrophages, which express the adiponectin receptor, adiponectin induced 
upregulation of IL-10 (36, 37).  Adiponectin also increased expression of CD36, acetyl 
CoA oxidase, and uncoupling protein 2 in skeletal muscle, while causing a decrease in 
CD36 in the liver (38).  In the endothelial cell, adiponectin was shown to inhibit the 
production of inflammatory cytokines and adhesion molecules such as intracellular 
adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule (VCAM) and E-selectin 
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(22).  Furthermore, adiponectin has been shown to increase endothelial nitric oxide 
synthase (eNOS) production leading to the production of nitric oxide (NO) in the 
vasculture to stimulate vasodialation (39).  Additionally, adiponectin inhibited TNF- 
induced activation of NF-B (40).  These studies, combined with our recent data suggest 
that adiponectin can play a protective role against key processes associated with 
atherosclerosis. 
 Leucine has recently been demonstrated to directly activate SIRT1 through an 
allosteric mechanism (41).  SIRT1 increases adiponectin gene transcription by activating 
Foxo1, thereby enhancing Foxo1 and C/EBP interaction (42), which then binds to the 
adiponectin promoter to increase transcription (42).  Adiponectin binding to AdipoR1 
increases calcium influx, causing activation of Ca
2+
/calmodulin-dependent protein kinase 
kinase  (CaMKK), which phosphorylates CaMK resulting in increased PGC-1 gene 
expression (21).  CaMKK also activates AMPK leading to increased NAD+ levels and 
subsequent activation of SIRT1, resulting in a positive feedback cycle.  The connection 
between adiponectin and decreased CD11b expression presumably occurs through 
suppression of NF-B.  NF-B is retained in the cytoplasm through interactions with 
inhibitory proteins from the inhibitory factor kappa B family (IB) (43).  Upon 
activation, IB is phosphorylated by IB kinase and becomes disassociated from NF-B, 
allowing NF-B translocation to the nucleus where it increases the transcription of pro-
inflammatory cytokines such as TNF- and MCP-1 (43, 44).  Adiponectin increases the 
expression and protein levels of IB causing NF-B to be retained in the cytoplasm, 
thereby reducing pro-inflammatory cytokine production (45).  The role of pro-
inflammatory cytokines such as TNF- and MCP-1 are to increase immune cell 
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infiltration to combat inflammatory stimuli.  CD11b is a common monocyte activation 
marker that responds to inflammatory cytokines, and it is required for monocyte adhesion 
and migration through the endothelium (46).  Therefore, decreased pro-inflammatory 
cytokine production at the adipocyte level and systemically can decreased CD11b 
expression resulting in decreased monocyte adhesion and infiltration through the 
endothelium. 
  In summary, our results indicate that leucine treatment of adipocytes reduces 
CD11b expression on fresh human monocytes and suggest that adiponectin present on 
ADMs mediate some of these effects.  Translation of these effects to a clinical setting 
could provide a framework to reduce obesity associated inflammation and further 
supports the ability of ADMs to serve as a communication vector between adipose tissue 
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Figure 4-1:  Effects of adipocyte CM on peripheral blood monocyte CD11b 
expression.  Fully differentiated 3T3-L1 adipocytes were treated for 48 hrs with leucine 
(open bars) or control (black bars).  Conditioned media (CM) was collected and the 
ADMs were separated from the supernatant (sup) by ultracentrifugation.  Whole CM, 
supernatant, and ADMs were incubated with whole blood for 2 hrs (A) and 18 hrs (B) at 
37C.  Results are presented as percent of monocytes (CD14+) that are CD11b+  SEM 






Figure 4-2:  Adiponectin knockdown efficiency and expression in 3T3-L1 cells.  
Differentiated 3T3-L1 cells (day 7) were untransfected, transfected with scrambled 
siRNA, or transfected with adiponectin siRNA (siAdipoQ) for 24 hrs and adiponectin 
mRNA levels were measured using RT-PCR (A; n=6).  Differentiated 3T3-L1 cells were 
untransfected (black bars) or transfected with siAdipoQ (open bars) as described above.  
Cells received no treatment (control) or treated with 0.5 mM leucine for 48 hrs and 
mRNA levels were measured by RT-PCR (B; n=3).  Results are presented as the ratio of 
adiponectin to ribosomal 18S  SEM.  * Denotes significance compared to untransfected 





Figure 4-3:  Adiponectin and ADMs mediate reduction in peripheral blood 
monocyte CD11b expression after 2 hours.  Differentiated 3T3-L1 adipocytes were 
untransfected (black bars) or transfected with siAdipoQ (open bars), and then treated for 
48 hrs with 0.5 mM leucine or not treated (control).  Whole conditioned media (A), 
isolated supernatant (B) or isolated ADMs (C) were incubated for 2 hrs. with whole 
blood.  Results are presented as percent of monocytes (CD14+) that are CD11b+  SEM 
(n=3).  * Denotes significant compared to untransfected (p< 0.002).  ** Denotes 






Figure 4-4:  Adiponectin and ADMs mediates reduction in peripheral blood 
monocyte CD11b expression after 18 hours.  Differentiated 3T3-L1 adipocytes were 
untransfected (black bars) or transfected with siAdipoQ (open bars), and then treated for 
48 hrs with 0.5 mM leucine or not treated (control).  Whole conditioned media (A), 
isolated supernatant (B) or isolated ADMs (C) were incubated for 18 hrs. with whole 
blood.  Results are presented as percent of monocytes (CD14+) that are CD11b+  SEM 
(n=3).  * Denotes significant compared to untransfected and control (p< 0.002).  ** 
































5.1  Conclusions: 
The data presented in this dissertation suggests that leucine, reduces monocyte – 
endothelial cell adhesion, and adipocyte derived microvesicles carrying adiponectin 
partially mediate these effects.  Treatment of adipocytes with leucine produces factors 
that decrease monocyte – endothelial cell adhesion, while treatment with calcitriol has the 
opposite effect.  The reduction in monocyte – endothelial cell adhesion observed with 
leucine treatment of adipocytes was further expanded using an ex vivo model using 
plasma samples from a recent clinical trial in which overweight and obese subjects were 
given either high (>3.5 servings/day) or low (<0.5 servings/day) dairy diets over a period 
of 12 weeks.  Compared to baseline plasma samples, the high dairy group decreased 
monocyte – endothelial cell adhesion after just 7 days and these effects were sustained 
throughout the 12 week study, while the low dairy group exhibited the opposite effect.  
These effects are due, in part, to an alteration in adipokine production, causing a decrease 
in pro-inflammatory cytokines (TNF-, MCP-1, IL-6, CRP) and an increase in anti-
inflammatory cytokines (adiponectin) (1, 2), resulting in a decrease in adhesion molecule 
expression on both monocyte (CD11b) and endothelial cells (CD54).  Our data shows 
that leucine treatment of adipocytes causes a decrease in peripheral blood monocyte 
CD11b expression, and the adipocyte derived microvesicles (ADMs) isolated from the 
conditioned media mimic the effects observed with whole conditioned medium, 
suggesting ADMs carry an active component(s), such as adiponectin, that mediates these 
effects.  We confirmed this concept by knocking down adiponectin production using 
siRNA, causing the previously observed reduction in CD11b expression to be blocked.  
Collectively, this data suggest that dairy products can be beneficial in reducing 
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inflammatory stress associated with obesity and adipocyte derived microvesicles play a 
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